This application relates generally to implantable medical devices and, more particularly, to implantable and rechargeable neural stimulators.
The automatic nervous system (ANS) regulates “involuntary” organs. The ANS includes the sympathetic nervous system and the parasympathetic nervous system. The sympathetic nervous system is affiliated with stress and the “fight or flight response” to emergencies. The parasympathetic nervous system is affiliated with relaxation and the “rest and digest response.” The ANS maintains normal internal function and works with the somatic nervous system. Autonomic balance reflects the relationship between parasympathetic and sympathetic activity. A change in autonomic balance is reflected in changes in heart rate, heart rhythm, contractility, remodeling, inflammation and blood pressure. Changes in autonomic balance can also be seen in other physiological changes, such as changes in abdominal pain, appetite, stamina, emotions, personality, muscle tone, sleep, and allergies, for example.
Neural stimulation therapy has been proposed for a variety of reasons. Reduced autonomic balance (increase in sympathetic and decrease in parasympathetic cardiac tone) during heart failure has been shown to be associated with left ventricular dysfunction and increased mortality. Research also indicates that increasing parasympathetic tone and reducing sympathetic tone may protect the myocardium from further remodeling and predisposition to fatal arrhythmias following myocardial infarction. Direct stimulation of the vagal parasympathetic fibers has been shown to reduce heart rate via the sympathetic nervous system. In addition, some research indicates that chronic stimulation of the vagus nerve may be of protective myocardial benefit following cardiac ischemic insult. Neural stimulation also has been proposed to alleviate pain and as a therapy for hypertension.
It can be difficult to anticipate the amount of energy needed for neural stimulation. For effective therapy, it may be necessary to stimulate neural targets intermittently or continuously. Also, high current levels may be effective for a larger area, or lower levels may be effective for a smaller area. A flexible power management system is needed to improve neural stimulation devices.
One aspect of the present subject matter relates to an implantable medical device. An embodiment of the device comprises a rechargeable power supply adapted to be recharged through an ultrasound signal, a neural stimulator connected to the rechargeable power supply, and a controller connected to the rechargeable power supply. The neural stimulator is adapted to generate a neural stimulation signal for delivery to a neural stimulation target through an electrode. The controller is further connected to the neural stimulator to control the neural stimulator according to a neural stimulation protocol. Other aspects are provided herein.
An embodiment of the implantable medical device comprises a structure, a rechargeable battery connected to the structure, a transducer adapted to charge the rechargeable battery using ultrasound energy, a sensor electrically connected to the rechargeable battery, a neural stimulator electrically connected to the rechargeable battery, and a controller electrically connected to the rechargeable battery and adapted to communicate with the sensor and the neural stimulator. The structure is selected from a group of structures consisting of: a structure adapted to be chronically implanted within a vessel, and a structure adapted to be subcutaneously implanted using a hypodermic needle.
One aspect of the present subject matter relates to a system. An embodiment of the system comprises at least two implantable medical devices, where each device being adapted to be chronically implanted into a vessel. Each device includes a rechargeable battery and an ultrasound transducer connected to the battery and adapted to recharge the battery using an ultrasound signal, a neural stimulator adapted to be powered by the battery, a sensor adapted to be powered by the battery, a controller electrically connected to a neural stimulator and the pressure sensor, and a communication module adapted to be powered by the battery and to transmit and receive ultrasound communication signals to another implantable medical device.
One aspect of the present subject matter relates to a method of operating an implantable medical device with a pressure sensor and a neural stimulator chronically implanted in a vessel. According to an embodiment of the method, a pressure is sensed within the vessel using the pressure sensor, a neural target is stimulated using the neural stimulator, a power supply is recharged using ultrasound signals.
This Summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. Other aspects will be apparent to persons skilled in the art upon reading and understanding the following detailed description and viewing the drawings that form a part thereof, each of which are not to be taken in a limiting sense. The scope of the present invention is defined by the appended claims and their equivalents.
The following detailed description of the present subject matter refers to the accompanying drawings which show, by way of illustration, specific aspects and embodiments in which the present subject matter may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present subject matter. Other embodiments may be utilized and structural, logical, and electrical changes may be made without departing from the scope of the present subject matter. References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope is defined only by the appended claims, along with the full scope of legal equivalents to which such claims are entitled.
Embodiments of the present subject matter provide implantable and rechargeable neural stimulators. Ultrasound energy can be used to recharge the stimulators. Some embodiments integrate a stimulator and a sensor in an implantable device, such that the device can autonomously provide stimulation therapy based on need. For example, a neural stimulator integrated with a pressure sensor can be activated when the sensor senses a higher blood pressure in the vasculature. The pressure sensor can use micro-electrical mechanical systems (MEMS) technology, for example. The devices can be implanted either subcutaneously or in the vasculature depending in the sensor-stimulator pair application. Examples of integrated sensors include sensors that can sense either electrical or physical physiologic parameters. These sensors can provide localized feedback for the neural stimulation. For example, a pressure sensor can sense high blood pressure and the stimulator can stimulate the appropriate nerve to lower the blood pressure. Such a system can be integrated into a device with a small form factor with its own power supply, such that the device is physically capable of being implanted through a hypodermic needle or intravascularly fed into a vessel, for example. A stent-like anchoring mechanism can be used in vasculature.
Embodiments also have the ability to wirelessly communicate other device(s), either inside or outside the body. Typically, such a system can communicate with another device within the body using ultrasound, which has minimal loss within the body. Communications with external devices can be performed using ultrasound, or inductive or RF telemetry. The intra-body communication allows the neural stimulation therapy to be to be coordinated with other implantable neural stimulators or other implantable devices such as from a cardiac rhythm management (CRM) device (e.g. pacemaker) also has such communication capability. Intrabody communication can significantly improve the efficacy of the neural stimulator, and the neural stimulation therapy.
The neural stimulator with integrated sensor can be chronically implanted to treat conditions such as hypertension and chronic pain. Some device embodiments have its own power source, and some device embodiments are powered remotely. Diagnostic and therapy functions can be performed at fixed times or based at least in part on feedback received from the sensor.
Physiology
Neural stimulation can be used to provide therapy for a variety of systemic abnormalities like hypertension. Hypertension is a cause of heart disease and other related cardiac co-morbidities. Hypertension occurs when blood vessels constrict. As a result, the heart works harder to maintain flow at a higher blood pressure, which can contribute to heart failure. A large segment of the general population, as well as a large segment of patients implanted with pacemakers or defibrillators, suffer from hypertension. The long term mortality as well as the quality of life can be improved for this population if blood pressure and hypertension can be reduced. Many patients who suffer from hypertension do not respond to treatment, such as treatments related to lifestyle changes and hypertension drugs. Hypertension generally relates to high blood pressure, such as a transitory or sustained elevation of systemic arterial blood pressure to a level that is likely to induce cardiovascular damage or other adverse consequences. Hypertension has been arbitrarily defined as a systolic blood pressure above 140 mm Hg or a diastolic blood pressure above 90 mm Hg. Hypertension occurs when blood vessels constrict. As a result, the heart works harder to maintain flow at a higher blood pressure. Consequences of uncontrolled hypertension include, but are not limited to, retinal vascular disease and stroke, left ventricular hypertrophy and failure, myocardial infarction, dissecting aneurysm, and renovascular disease.
The automatic nervous system (ANS) regulates “involuntary” organs, while the contraction of voluntary (skeletal) muscles is controlled by somatic motor nerves. Examples of involuntary organs include respiratory and digestive organs, and also include blood vessels and the heart. Often, the ANS functions in an involuntary, reflexive manner to regulate glands, to regulate muscles in the skin, eye, stomach, intestines and bladder, and to regulate cardiac muscle and the muscle around blood vessels, for example.
The ANS includes, but is not limited to, the sympathetic nervous system and the parasympathetic nervous system. The sympathetic nervous system is affiliated with stress and the “fight or flight response” to emergencies. Among other effects, the “fight or flight response” increases blood pressure and heart rate to increase skeletal muscle blood flow, and decreases digestion to provide the energy for “fighting or fleeing.” The parasympathetic nervous system is affiliated with relaxation and the “rest and digest response” which, among other effects, decreases blood pressure and heart rate, and increases digestion to conserve energy. The ANS maintains normal internal function and works with the somatic nervous system.
The heart rate and force is increased when the sympathetic nervous system is stimulated, and is decreased when the sympathetic nervous system is inhibited (the parasympathetic nervous system is stimulated). An afferent nerve conveys impulses toward a nerve center, such as a vasomotor center which relates to nerves that dilate and constrict blood vessels to control the size of the blood vessels. An efferent nerve conveys impulses away from a nerve center.
A pressoreceptive region or field is capable of sensing changes in pressure, such as changes in blood pressure. Pressoreceptor regions are referred to herein as baroreceptors, which generally include any sensors of pressure changes. The baroreflex functions as a negative feedback system, and relates to a reflex mechanism triggered by stimulation of a baroreceptor. Increased pressure stretches blood vessels, which in turn activates baroreceptors in the vessel walls. Activation of baroreceptors naturally occurs through internal pressure and stretching of the arterial wall, causing baroreflex inhibition of sympathetic nerve activity (SNA) and a reduction in systemic arterial pressure. An increase in baroreceptor activity induces a reduction of SNA, which reduces blood pressure by decreasing peripheral vascular resistance.
Direct electrical stimulation has been applied to the vagal nerve and carotid sinus. Research has indicated that electrical stimulation of the carotid sinus nerve can result in reduction of experimental hypertension, and that direct electrical stimulation to the pressoreceptive regions of the carotid sinus itself brings about reflex reduction in experimental hypertension.
Stimulating the sympathetic and parasympathetic nervous systems can have effects other than heart rate and blood pressure. For example, stimulating the sympathetic nervous system dilates the pupil, reduces saliva and mucus production, relaxes the bronchial muscle, reduces the successive waves of involuntary contraction (peristalsis) of the stomach and the motility of the stomach, increases the conversion of glycogen to glucose by the liver, decreases urine secretion by the kidneys, and relaxes the wall and closes the sphincter of the bladder. Stimulating the parasympathetic nervous system (inhibiting the sympathetic nervous system) constricts the pupil, increases saliva and mucus production, contracts the bronchial muscle, increases secretions and motility in the stomach and large intestine, and increases digestion in the small intention, increases urine secretion, and contracts the wall and relaxes the sphincter of the bladder. The functions associated with the sympathetic and parasympathetic nervous systems are many and can be complexly integrated with each other. Thus, an indiscriminate stimulation of the sympathetic and/or parasympathetic nervous systems to achieve a desired response, such as vasodilation, in one physiological system may also result in an undesired response in other physiological systems. Aspects of the present subject matter provide implantable medical devices with a form factor (physical size and shape) adapted for minimally-intrusive implantation that allows the devices to be positioned to specifically stimulate desired nerves.
The baroreflex is a reflex triggered by stimulation of a baroreceptor. A baroreceptor includes any sensor of pressure changes, such as sensory nerve endings in the wall of the auricles of the heart, cardiac fat pads, vena cava, aortic arch and carotid sinus, that is sensitive to stretching of the wall resulting from increased pressure from within, and that functions as the receptor of the central reflex mechanism that tends to reduce that pressure. A baroreflex response can be induced by stimulating some afferent nerve trunks, such as the vagus, aortic and carotid nerves, leading from the sensory nerve endings. Stimulating a baroreflex inhibits sympathetic nerve activity (stimulates the parasympathetic nervous system) and reduces systemic arterial pressure by decreasing peripheral vascular resistance and cardiac contractility.
Some aspects of the present subject matter locally stimulate specific nerve endings, such as nerve endings near or by arterial walls, rather than stimulate afferent nerve trunks in an effort to stimulate a desire response (e.g. reduced hypertension) while reducing the undesired effects of indiscriminate stimulation of the nervous system. For example, some embodiments stimulate baroreceptor sites in the pulmonary artery. Some embodiments of the present subject matter involve stimulating either baroreceptor sites or nerve endings in the aorta, the carotid sinus, the chambers of the heart, the fat pads of the heart, and some embodiments of the present subject matter involve stimulating an afferent nerve trunk, such as the vagus, carotid and aortic nerves, and various branches of these nerves such as a cardiac branch of the vagus nerve. Some embodiments stimulate afferent nerve trunks using an intravascularly placed electrode positioned in a blood vessel proximate to the nerve, such that the electrical stimulation transvascularly passes through the vessel wall to stimulate the nerve trunk.
Neural stimulation has been proposed to provide remodeling therapy to reverse the stiffening process caused by hypertension, and to provide a therapy for myocardial infarction to reduce or prevent myocardial damage caused by highly stressed regions of the heart. With respect to remodeling, the slow and progressive lowering of blood pressure enables the slower reversion of the stiffening process through the reverse remodeling. Blood pressure is reduced without compromising cardiac output in the process, thus avoiding undesired patient symptoms. With respect to myocardial infarction therapy, it is noted that an increased baroreflex stimulation compensates for reduced baroreflex sensitivity through quick vasodilation and associated decrease in systemic blood pressure, and improves the clinical outcome in patients following a myocardial infarction.
Neural stimulation can also be used to stimulate sensory nerves to block pain signals from reaching the brain. The stimulation can stimulate production of endorphins, which are chemicals produced in the brain, often in response to stress and pain, that reduce pain perception. In addition to blocking neural signals to block pain, the neural stimulation can be used to block or stimulate other neural pathways, such as to prevent or stimulate a particular muscle contraction.
Device Embodiments
The illustrated power and communication circuitry 102 includes a rechargeable battery, which is capable of being recharged using ultrasound signals. In the embodiment of
According to one embodiment, the chronically-implanted device is an intravascular device. For example, one device embodiment has the form of a stent or a stent-like device. Some device embodiments communicate to other implantable medical devices 114 using communication link 116. Some embodiments use an ultrasound communication link 116. According to various embodiments, the device functions as a satellite and communicates to a planet by way of ultrasound energy.
According to one embodiment, the chronically-implanted device includes control circuitry 104 to control the functions of one or more of the subsystems or components shown in
The illustrated device further includes neural stimulation circuitry 106. Various embodiments of the device also includes sensor circuitry 108. The neural stimulation circuitry is used to apply electrical stimulation pulses to desired neural target sites, such as baroreceptor sites in the pulmonary artery, through one or more stimulation electrodes. In various embodiments, at least one electrode is connected to the neural stimulation circuitry using a lead such that the neural stimulation circuitry applies electrical stimulation through the lead and electrode. In various embodiments, at least one electrode is wirelessly coupled to the neural stimulation circuitry such that the neural stimulation circuitry wirelessly applies electrical stimulation to the electrode. Such wireless embodiments provide additional flexibility in placement of the electrode(s) and device. In various embodiments, at least one electrode is integrated with or otherwise formed on the housing of the device such that the neural stimulation circuitry applies electrical stimulation through the electrode on the housing. The sensor circuitry can be used to provide feedback for the neural stimulation. For example, the sensing circuit 108 can be used to detect and process ANS nerve activity and/or surrogate parameters such as blood pressure, respiration and the like, to determine the ANS activity.
According to various embodiments, the stimulator circuitry 106 includes modules to set any one or any combination of two or more of the following pulse features: the amplitude of the stimulation pulse, the frequency of the stimulation pulse, the burst frequency or duty cycle of the pulse, and the wave morphology of the pulse. Examples of wave morphology include a square wave, triangle wave, sinusoidal wave, and waves with desired harmonic components to mimic white noise such as is indicative of naturally-occurring baroreflex stimulation.
Various implantable neural stimulator embodiments include an integrated pressure sensor (IPS), to monitor changes in blood pressure, for example. Thus, the sensor monitors the effect of the neural stimulation. In various embodiments, for example, micro-electrical mechanical systems (MEMS) technology is used to sense the blood pressure. Some sensor embodiments determine blood pressure based on a displacement of a membrane. The stimulator and sensor functions can be integrated, even if the stimulator and sensors are located in separate devices.
This device, for example, is capable of being intravascularly introduced or subcutaneously introduced by a hypodermic needle to stimulate a neural target, such as the baroreceptor sites in the pulmonary artery, the aortic arch, the ligamentum arteriosum, the coronary sinus, and the atrial and ventricular chambers, and neural targets such as the cardiac fat pads.
Thus, various embodiments of the present subject matter provide an implantable neural stimulation device that automatically modulates neural stimulation using an IPS based, at least in part, on localized feedback from the integrated pressure sensor. This localized sensing improves feedback control. According to various embodiments, the device monitors pressure parameters such as mean arterial pressure, systolic pressure, diastolic pressure and the like. As mean arterial pressure increases or remains above a programmable target pressure, for example, the device stimulates the baroreflex at an increased rate to reduce blood pressure and control hypertension. As mean arterial pressure decreases towards the target pressure, the device responds by reducing the stimulation of the baroreflex. In various embodiments, the algorithm takes into account the current metabolic state (cardiac demand) and adjusts neural stimulation accordingly. A neural stimulation device having an IPS is able to automatically modulate neural stimulation, which allows an implantable NS device to determine the level of hypertension in the patient and respond by delivering the appropriate level of therapy.
An aspect of the present subject matter relates to a chronically-implanted stimulation device specially designed to treat hypertension by monitoring blood pressure and stimulating baroreceptors to activate the baroreflex and inhibit sympathetic discharge from the vasomotor center. Baroreceptors are located in various anatomical locations such as the carotid sinus and the aortic arch. Other baroreceptor locations include the pulmonary artery, including the ligamentum arteriosum, and sites in the atrial and ventricular chambers. In various embodiments, the neural stimulation device is integrated into a pacemaker/defibrillator or other electrical stimulator system. Components of the system include a pulse generator, sensors to monitor blood pressure or other pertinent physiological parameters, electrodes to apply electrical stimulation to neural targets, algorithms operated on by a controller to determine the when and how to administer stimulation, and algorithms operated on by the controller to manipulate data for display and patient management. The controller is adapted to control the neural stimulator to provide a neural stimulation therapy using feedback from the pressure sensor. According to various embodiments, the therapy includes one or more of a treatment following myocardial infarction, a treatment to alleviate pain, and a therapy for hypertension. As those of ordinary skill in the art will understand upon reading and comprehending this disclosure, other neural stimulation therapies can be performed.
A system according to these embodiments can be used to augment partially successful treatment strategies. As an example, undesired side effects may limit the use of some pharmaceutical agents. The combination of a system according to these embodiments with reduced drug doses may be particularly beneficial.
Form Factor (Size/Shape)
According to one embodiment, the electrical stimulation functions provided by the intravascular device involves only a minimally invasive surgery, even when several electrodes are placed for multisite pacing. Strategies that incorporate multisite pacing are believed to offer therapeutic advantages.
The chronically-implanted device diminishes problems associated with invasive surgical procedures because the device is small and is capable of being placed by a hypodermic needle or a catheter, for example, into position through the vascular network or through the lumen of other canals or tubular structures of a biosystem.
According to various embodiments, the chronically-implanted device of the present subject matter may be formed to function as a variety of stents. These stents include, but are not limited to, a coronary stent, a vascular stent, a tracheobronchial stent, a colonic/duodenal stent, an esophageal stent, a biliary stent, a urological stent, a neurovascular stent, an abdominal aortic aneurysm stent, a renal stent, and a carotid stent.
The stent-like structure of one embodiment of a chronically-implanted device includes at least two conducting portions separated by an insulator. One of the conducting portions functions as an anode and another functions as a cathode. These conducting portions are used, according to various embodiments of the chronically-implanted device, to provide electrical therapy (e.g. neural stimulation), to receive power transmissions, and/or to receive and transmit communication transmissions.
Rechargeable Power Supply
The chronically-implanted device includes power circuitry. According to various embodiments, for example, the power circuitry forms part of the power/communication circuit 102 of
Communication
The chronically-implanted device includes communication circuitry used to communicate to an external device. According to various embodiments, for example, the communication circuitry forms part of the power/communication circuits 102 of
Neural Stimulator
According to one embodiment, the neural stimulator has adjustable stimulation parameters such as pulse width, frequency, duty cycle, burst duration, amplitude, stimulation modes (bi-polar or uni-polar, for example), and stimulation site if multiple sites are available. According to one embodiment, the neural stimulation circuitry receives its parameters from the controller.
The device includes electrode(s) to provide neural stimulation. Some device embodiments sense electrical signals with electrode(s). Some electrode embodiments are connected to the device by a lead or tether. In some embodiments, the electrode is attached to the device housing; and in some embodiments, the electrode forms at least part of the device housing.
Electrode embodiments include intravascularly-placed electrodes and electrodes placed subcutaneously. With respect to intravascularly-placed embodiments, at least one an electrode is placed in a blood vessel and positioned to transvascularly stimulate a nerve on or near the extravascular surface of the vessel. Transvascular stimulation avoids direct contact with nerves during stimulation and reduces problems associated with neural inflammation or injury induced by direct stimulation. Transvascular stimulation using intravascularly-fed leads provides relatively non-invasive access to anatomical targets and points of innervation.
In an example, the expandable electrode includes a mesh, at least part of which is electrically conductive. In an example, the expandable electrode is formed from Platinum or Platinum-Iridium. In an embodiment, the expandable electrode is similar to a stent. A nerve trunk extends on or near an extravascular surface of the blood vessel. An expandable electrode can be implanted at or near a location in the blood vessel where the nerve trunk crosses the blood vessel. In an example, the expandable electrode transmits neural stimulation energy through a predetermined surface area of the wall of a blood vessel. In an example, the expandable electrode has a length that provides enough surface area that there is at least some flexibility in the placement of the expandable electrode in the vessel with respect to the target nerve. In an example, the length of the expandable electrode is about 0.5 to 2.0 cm.
In an embodiment, the entire surface area of the expandable electrode that touches the blood vessel wall is conductive. In an embodiment, at least a part of the surface area of the electrode is non-conductive. For example, an electrode can be formed and positioned to deliver stimulation to through a conductive part of the electrode to a portion of a blood vessel that is proximate a nerve. The expandable electrode has an expanded diameter that is sized for implantation in a blood vessel of a particular size range. In one example, where the electrode is size for implantation in the internal jugular vein, the expanded diameter is about 0.5 to 1.5 cm, and the length of the electrode is about 1.0 cm.
In an example, the expandable electrode is covered with a drug, such as a drug that prevents occlusion, or a drug that reduces inflammation of the blood vessel near the electrode. The expandable electrode is coupled to a power source that delivers an electrical stimulation. The electrode can be coupled to the power source through a lead, or the electrode can form at least part of a device structure that contains the power source.
The electrode(s) may be implanted in various locations in the body, including a variety of locations near a trunk or branch of a sympathetic or parasympathetic nerve system. In an example, the electrode transvascularly stimulates a peripheral nerve trunk. Examples of a peripheral nerve trunk include the vagus nerve, aortic nerve, and carotid sinus nerve. In another example, the electrode stimulates a nerve branch, such as a vagal cardiac branch. The electrode(s) can be implanted in various vessels or chambers such as the superior vena cava (SVC) to transvascularly stimulate a nerve or nerve trunk on or near the SVC, and a coronary sinus.
Electrodes can be implanted within the atria, the ventricle, superior vena cava, inferior vena cava, aorta, right pulmonary veins, and right pulmonary artery, and coronary sinus. An electrode can be implanted in one or more of the blood vessels listed above at a location where a nerve, nerve branch, or nerve trunk passes an extravascular surface of the blood vessel. The implanted electrode transvascularly stimulates a nerve, nerve branch, or nerve trunk through the blood vessel. In one example, an electrode is implanted in the SVC near a vagal nerve trunk. In another example, an electrode is implanted in the coronary sinus near a vagal nerve trunk.
In another example, a cardiac fat pad is transvascularly stimulated by an implanted electrode. A cardiac fat pad is located between the superior vena cava and aorta, a cardiac fat pad is located proximate to the right cardiac veins, and a cardiac fat pad is located proximate to the inferior vena cava and left atrium. Electrodes implanted in the superior vena cava, aorta, cardiac veins, inferior vena cava or coronary sinus can be used to stimulate various cardiac fat pads.
Electrodes can be implanted at locations in blood vessels near a vagus nerve. The right vagus nerve trunk extends near the carotid artery and subclavian artery. The left vagus nerve extends near the carotid artery and subclavian artery. Additionally, electrodes can be implanted in the carotid sinus near the carotid sinus nerve.
The left vagus nerve extends next to a subclavian artery also extends past the ligamentum arteriosum. Various nerves extend around the arch of the aorta. The anterior pulmonary plexus crosses the left pulmonary artery. The right vagus nerve extends past a subclavian artery and the cupola of pleura. Cardiac nerves extend past the brachiocephalic trunk near the trachea. Cardiac nerves also extend past the arch of an azygos vein to the right pulmonary artery. A left phrenic nerve extends past a cupola of pleura, an internal thoracic artery, and left pulmonary artery. The vagus nerve, recurrent laryngeal nerves, cardiac nerves, and the anterior pulmonary plexus extend near the left pulmonary artery and ligamentum arteriosum. An expandable electrode, such as a stent, is chronically implantable in these blood vessels to transvascularly stimulate a nerve or nerve trunk that extends on or near these blood vessel. For example, the vagus nerve can be transvascularly stimulated from the azygos vein or internal jugular vein. An afferent nerve conveys impulses toward a nerve center, and an efferent nerve conveys impulses away from a nerve center. Both afferent and efferent nerves can be stimulated transvascularly. In other examples, nerve trunks innervating other organs, such as the lungs or kidneys are transvascularly stimulated.
Sensor(s)
According to one embodiment, the sensor functions provided by the device are capable of providing continuous intravascular measurements, such as blood pressure, blood flow and vessel size. According to one embodiment, the chronically-implanted device, or system of devices, communicates with a central unit, such as an implantable device, and monitors blood flow, blood pressure, and vessel inner diameter.
According to various embodiments, Micro-Electro-Mechanical Systems (MEMS) technology is used to fabricate the required circuitry for the chronically-implanted device on silicon substrate. Currently, for example, the MEMS circuitry is between about 1 mm×3 mm for some of the present applications; however, the MEMS circuitry is capable of being otherwise sized. MEMS devices have been used in catheter-based systems to measure intracardiac pressure and temperature.
In general, a MEMS device contains micro-circuitry on a tiny silicon chip into which some mechanical device such as a sensor has been manufactured. These chips are able to be built in large quantities at low cost, making the MEMS device cost-effective. MEMS technology integrates mechanical elements, sensors, actuators, and electronics on a common silicon substrate using microfabrication technology. MEMS combines silicon-based microelectronics with microsensors and microactuators to provide a complete system on a chip. The micromechanical components are fabricated using micromachining processes that are compatible with the integrated circuit process sequences. Parts of the silicon wafer are selectively etched away or new structural layers are added to form the mechanical and electromechanical devices. According to various embodiments of the chronically-implanted device, at least one of the components (i.e. the power circuitry, the communication circuitry, the control circuitry, the stimulation circuitry, and the sensing circuitry) are integrated onto silicon MEMS technology to reduce size.
Examples of pressure sensors include capacitive membrane and piezoelectric sensors. According to various embodiments, the capacitive membrane sensor is used to measure pressure within the vessel wall, to derive flow, to derive rate, to monitor cardiac output, to monitor hemodynamic stability, and to monitor Electro-Mechanical Dissociation (EMD). It was stated earlier in the background that there is a correlation between cardiac electrical abnormalities and coronary vascular abnormalities. However, it is possible that the electrical functions appear normal but the mechanical functions are abnormal, or that the mechanical functions are normal but the electrical functions appear abnormal. EMD identifies conditions in which electrical and mechanical functions of the biological system are not in accord or agreement with each other.
According to various embodiments, the piezoresistive sensor is used to measure pressure within the vessel wall, to derive flow, to derive rate, to monitor cardiac output, to monitor hemodynamic stability, and to monitor EMD. In one embodiment the piezoresistive sensor is used to measure contraction strength of the heart.
System Embodiments
According to one embodiment, the chronically-implanted device is incorporated as one or more satellites in a satellite-planet configuration.
In general, the planet is implanted or externally retained. The planet is capable of wirelessly communicating, i.e. without a direct electrical connection, to each satellite using ultrasound, for example, or is capable of being tethered to each satellite. The planet individually commands each satellite to provide sensing functions and therapy functions such as delivering electrical pulses or drugs. In another embodiment, the satellites function autonomously and are in communication with the planet. This communication is initiated by the planet and/or by the satellite in various embodiments. Additionally, each satellite is capable of determining when a sense event has occurred, along with an identifying code indicating to the planet which satellite detected the sense event. In one embodiment, the planet processes the encoded signals received from the network of satellites, assigns time values to each satellite when that satellite detects a sense event, compares the time values to a template of normal time values, and determines if a therapy should be applied. Further, the planet selects and applies the appropriate therapy for the sensed event. In various embodiments, the satellites are self-powered using a rechargeable battery capable of being recharged using ultrasound.
Therapy Examples
According to various embodiments, the therapy includes one or more of a treatment following myocardial infarction, a treatment to alleviate pain, and a therapy for hypertension.
Neural stimulation therapies can be used to treat one or more of a variety of conditions, including but not limited to arrhythmias, heart failure, syncope, or orthostatic intolerance. In an example, an efferent peripheral nerve is transvascularly stimulated by an implanted expandable electrode. In another example, an afferent peripheral nerve is stimulated.
In an example, electrical stimulation is transvascularly delivered to a parasympathetic nerve to reduce chronotropic, ionotropic, and dromotropic responses in the heart. In a therapy example, electrical stimulation is transvascularly delivered to a parasympathetic nerve trunk during heart failure. In another therapy example, electrical stimulation is transvascularly delivered to a parasympathetic nerve trunk following a myocardial infarction to protect against arrhythmias or prevent cardiac remodeling.
Transvascular stimulation of a vagus nerve trunk is used in a number of therapies. In an example, vagal nerve stimulation simultaneously increases parasympathetic tone and decreases sympathetic myocardial tone. In an example, a vagus nerve trunk is transvascularly stimulated following cardiac ischemic insult. Increased sympathetic nervous activity following ischemia often results in increased exposure of the myocardium to epinephrine and norepinephrine. These catecholamines activate intracellular pathways within the myocytes, which lead to myocardial death and fibrosis. This effect is inhibited by stimulation of the parasympathetic nerves, such as vagus nerves. In an example, vagal stimulation from the SVC lowers heart rate, overall blood pressure, and left ventricular pressure. Stimulation of the vagal cardiac nerves following myocardial infarction, or in heart failure patients, can be beneficial in preventing further remodeling and arrhythmogenesis.
In other examples, transvascular neural stimulation is used to treat other conditions such as hypertrophic cardiomyopathy (HCM) or neurogenic hypertension, where an increase parasympathetic cardiac tone and reduction in sympathetic cardiac tone is desired. In another example, a bradycardia condition is treated by transvascularly stimulating a sympathetic nerve trunk. In another example, the ionotropic state of the heart is increased by transvascularly stimulating a sympathetic nerve trunk.
Another example of a neural stimulation therapy includes Functional Electric Stimulation (FES), such as may be used in a therapy for foot drop, standing, walking, hand grasp, and shoulder control. FES can be used as a therapy for spinal cord injuries, and its debilitating effect on a variety of bodily functions. In various embodiments, electrodes used in FES therapies can be subcutaneously placed near or next to a desired nerve for the therapy. Other examples include therapies for the treatment of stroke, epilepsy, eating disorders, sleeping disorders, and pain. Various facial nerves can be stimulated to treat facial droop, migraine headaches and other headaches, for example. These therapy examples are not intended to be exclusive, as those of ordinary skill in the art will understand, upon reading and understanding this disclosure, how to apply the present subject matter for other neural stimulation therapies.
This disclosure includes several processes, circuit diagrams, and structures. The present invention is not limited to a particular process order or logical arrangement. Although specific embodiments have been illustrated and described herein, it will be appreciated by those of ordinary skill in the art that any arrangement which is calculated to achieve the same purpose may be substituted for the specific embodiments shown. This application is intended to cover adaptations or variations. It is to be understood that the above description is intended to be illustrative, and not restrictive. Combinations of the above embodiments, and other embodiments, will be apparent to those of skill in the art upon reviewing the above description. The scope of the present invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
This application is a continuation of U.S. application Ser. No. 13/402,196, filed Feb. 22, 2012, now issued as U.S. Pat. No. 8,315,702, which is a continuation of U.S. application Ser. No. 12/613,094, filed Nov. 5, 2009, now issued as U.S. Pat. No. 8,126,561, which is a divisional of U.S. application Ser. No. 11/256,907, filed Oct. 24, 2005, now issued as U.S. Pat. No. 7,616,990, each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3557796 | Keller, Jr. et al. | Jan 1971 | A |
3650277 | Sjostrand et al. | Mar 1972 | A |
3692027 | Ellinwood, Jr. | Sep 1972 | A |
4003379 | Ellinwood, Jr. | Jan 1977 | A |
4082097 | Mann et al. | Apr 1978 | A |
4146029 | Ellinwood, Jr. | Mar 1979 | A |
4217910 | Khalil | Aug 1980 | A |
4281664 | Duggan | Aug 1981 | A |
4299220 | Dorman | Nov 1981 | A |
4522208 | Buffet | Jun 1985 | A |
4544371 | Dormandy, Jr. et al. | Oct 1985 | A |
4556063 | Thompson et al. | Dec 1985 | A |
4686987 | Salo et al. | Aug 1987 | A |
4770177 | Schroeppel | Sep 1988 | A |
4791931 | Slate | Dec 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4897987 | Spalla | Feb 1990 | A |
4907336 | Gianturco | Mar 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4944299 | Silvian | Jul 1990 | A |
4987897 | Funke | Jan 1991 | A |
4994033 | Shockey et al. | Feb 1991 | A |
5024222 | Thacker | Jun 1991 | A |
5040533 | Fearnot | Aug 1991 | A |
5041107 | Heil, Jr. | Aug 1991 | A |
5042497 | Shapland | Aug 1991 | A |
5052388 | Sivula et al. | Oct 1991 | A |
5058581 | Silvian | Oct 1991 | A |
5078736 | Behl | Jan 1992 | A |
5087243 | Avitall | Feb 1992 | A |
5111815 | Mower | May 1992 | A |
5127404 | Wyborny et al. | Jul 1992 | A |
5178618 | Kandarpa | Jan 1993 | A |
5181519 | Bible | Jan 1993 | A |
5190035 | Salo et al. | Mar 1993 | A |
5199428 | Obel et al. | Apr 1993 | A |
5203326 | Collins | Apr 1993 | A |
5220917 | Cammilli et al. | Jun 1993 | A |
5226424 | Bible | Jul 1993 | A |
5243980 | Mehra | Sep 1993 | A |
5269301 | Cohen | Dec 1993 | A |
5284136 | Hauck et al. | Feb 1994 | A |
5292321 | Lee | Mar 1994 | A |
5300875 | Tuttle | Apr 1994 | A |
5305745 | Zacouto | Apr 1994 | A |
5318592 | Schaldach | Jun 1994 | A |
5324316 | Schulman et al. | Jun 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5342408 | deCoriolis et al. | Aug 1994 | A |
5345933 | Peterson et al. | Sep 1994 | A |
5353800 | Pohndorf et al. | Oct 1994 | A |
5354318 | Taepke | Oct 1994 | A |
5356425 | Bardy et al. | Oct 1994 | A |
5368028 | Palti | Nov 1994 | A |
5403351 | Saksena | Apr 1995 | A |
5404877 | Nolan et al. | Apr 1995 | A |
5411531 | Hill et al. | May 1995 | A |
5416695 | Stutman et al. | May 1995 | A |
5417717 | Salo et al. | May 1995 | A |
5436548 | Thomas | Jul 1995 | A |
5437285 | Verrier et al. | Aug 1995 | A |
5456692 | Smith, Jr. et al. | Oct 1995 | A |
5460605 | Tuttle et al. | Oct 1995 | A |
5496360 | Hoffmann et al. | Mar 1996 | A |
5499971 | Shapland et al. | Mar 1996 | A |
5501703 | Holsheimer et al. | Mar 1996 | A |
5507784 | Hill et al. | Apr 1996 | A |
5522854 | Ideker et al. | Jun 1996 | A |
5531779 | Dahl et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5551953 | Lattin et al. | Sep 1996 | A |
5556421 | Prutchi et al. | Sep 1996 | A |
5562711 | Yerich et al. | Oct 1996 | A |
5562713 | Silvian | Oct 1996 | A |
5578061 | Stroetmann et al. | Nov 1996 | A |
5579876 | Adrian et al. | Dec 1996 | A |
5586556 | Spivey et al. | Dec 1996 | A |
5607418 | Arzbaecher | Mar 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5634899 | Shapland et al. | Jun 1997 | A |
5637113 | Tartaglia et al. | Jun 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5662689 | Elsberry et al. | Sep 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5690682 | Buscemi et al. | Nov 1997 | A |
5693075 | Plicchi et al. | Dec 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5703125 | Bovy et al. | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5720770 | Nappholz et al. | Feb 1998 | A |
5730125 | Prutchi et al. | Mar 1998 | A |
5749900 | Schroeppel et al. | May 1998 | A |
5766192 | Zacca | Jun 1998 | A |
5775338 | Hastings | Jul 1998 | A |
5792187 | Adams | Aug 1998 | A |
5800498 | Obino et al. | Sep 1998 | A |
5814089 | Stokes et al. | Sep 1998 | A |
5817131 | Elsberry et al. | Oct 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5836935 | Ashton et al. | Nov 1998 | A |
5843142 | Sultan | Dec 1998 | A |
5846218 | Brisken et al. | Dec 1998 | A |
5876433 | Lunn | Mar 1999 | A |
5893881 | Elsberry et al. | Apr 1999 | A |
5899917 | Edwards et al. | May 1999 | A |
5899928 | Sholder et al. | May 1999 | A |
5906636 | Casscells, III et al. | May 1999 | A |
5913876 | Taylor et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5921954 | Mohr, Jr. et al. | Jul 1999 | A |
5925066 | Kroll et al. | Jul 1999 | A |
5932991 | Ahuja et al. | Aug 1999 | A |
5944710 | Dev et al. | Aug 1999 | A |
5949659 | Lesche | Sep 1999 | A |
5954761 | Macheck et al. | Sep 1999 | A |
5967986 | Cimochowski et al. | Oct 1999 | A |
5972029 | Fuisz | Oct 1999 | A |
5980566 | Alt et al. | Nov 1999 | A |
5987746 | Williams et al. | Nov 1999 | A |
5991668 | Leinders et al. | Nov 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6016447 | Juran et al. | Jan 2000 | A |
6016448 | Busacker et al. | Jan 2000 | A |
6021350 | Mathson | Feb 2000 | A |
6053913 | Tu et al. | Apr 2000 | A |
6058331 | King | May 2000 | A |
6073048 | Kieval et al. | Jun 2000 | A |
6102908 | Tu et al. | Aug 2000 | A |
6112116 | Fischell et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6115636 | Ryan | Sep 2000 | A |
6117085 | Picatti et al. | Sep 2000 | A |
6128526 | Stadler et al. | Oct 2000 | A |
6134470 | Hartlaub | Oct 2000 | A |
6140740 | Porat et al. | Oct 2000 | A |
6141588 | Cox et al. | Oct 2000 | A |
6144878 | Schroeppel et al. | Nov 2000 | A |
6154675 | Juran et al. | Nov 2000 | A |
6161042 | Hartley et al. | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6168801 | Heil, Jr. et al. | Jan 2001 | B1 |
6178349 | Kieval | Jan 2001 | B1 |
6179824 | Eggers et al. | Jan 2001 | B1 |
6181966 | Nigam | Jan 2001 | B1 |
6198394 | Jacobsen et al. | Mar 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6205361 | Kuzma et al. | Mar 2001 | B1 |
6206914 | Soykan et al. | Mar 2001 | B1 |
6213942 | Flach et al. | Apr 2001 | B1 |
6231516 | Keilman et al. | May 2001 | B1 |
6237398 | Porat et al. | May 2001 | B1 |
6240314 | Plicchi et al. | May 2001 | B1 |
6240316 | Richmond et al. | May 2001 | B1 |
6254573 | Haim et al. | Jul 2001 | B1 |
6256233 | Glass | Jul 2001 | B1 |
6256538 | Ekwall | Jul 2001 | B1 |
6266564 | Hill et al. | Jul 2001 | B1 |
6272377 | Sweeney et al. | Aug 2001 | B1 |
6272379 | Fischell et al. | Aug 2001 | B1 |
6277078 | Porat et al. | Aug 2001 | B1 |
6278894 | Salo et al. | Aug 2001 | B1 |
6285907 | Kramer et al. | Sep 2001 | B1 |
6285909 | Sweeney et al. | Sep 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6292703 | Meier et al. | Sep 2001 | B1 |
6298272 | Peterfeso et al. | Oct 2001 | B1 |
6308104 | Taylor et al. | Oct 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6317615 | KenKnight et al. | Nov 2001 | B1 |
6339720 | Anzellini et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6349233 | Adams | Feb 2002 | B1 |
6358202 | Arent | Mar 2002 | B1 |
6361522 | Scheiner et al. | Mar 2002 | B1 |
6361780 | Ley et al. | Mar 2002 | B1 |
6371922 | Baumann et al. | Apr 2002 | B1 |
6375666 | Mische | Apr 2002 | B1 |
6381499 | Taylor et al. | Apr 2002 | B1 |
6400982 | Sweeney et al. | Jun 2002 | B2 |
6411845 | Mower | Jun 2002 | B1 |
6421557 | Meyer | Jul 2002 | B1 |
6424847 | Mastrototaro et al. | Jul 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6442424 | Ben-Haim et al. | Aug 2002 | B1 |
6443949 | Altman | Sep 2002 | B2 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6453195 | Thompson | Sep 2002 | B1 |
6456866 | Tyler et al. | Sep 2002 | B1 |
6459917 | Gowda et al. | Oct 2002 | B1 |
6468263 | Fischell et al. | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6477418 | Plicchi et al. | Nov 2002 | B2 |
6487442 | Wood | Nov 2002 | B1 |
6487450 | Chen et al. | Nov 2002 | B1 |
6493585 | Plicchi et al. | Dec 2002 | B2 |
6501983 | Natarajan et al. | Dec 2002 | B1 |
6507753 | Xue et al. | Jan 2003 | B1 |
6511477 | Altman et al. | Jan 2003 | B2 |
6511500 | Rahme | Jan 2003 | B1 |
6518245 | Anderson et al. | Feb 2003 | B1 |
6519488 | KenKnight et al. | Feb 2003 | B2 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6532381 | Bayer et al. | Mar 2003 | B2 |
6532388 | Hill et al. | Mar 2003 | B1 |
6542774 | Hill et al. | Apr 2003 | B2 |
6564096 | Mest | May 2003 | B2 |
6571121 | Schroeppel et al. | May 2003 | B2 |
6584362 | Scheiner et al. | Jun 2003 | B1 |
6609023 | Fischell et al. | Aug 2003 | B1 |
6611713 | Schauerte | Aug 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6645145 | Dreschel et al. | Nov 2003 | B1 |
6648881 | KenKnight et al. | Nov 2003 | B2 |
6656960 | Puskas | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6689117 | Sweeney et al. | Feb 2004 | B2 |
6690971 | Schauerte et al. | Feb 2004 | B2 |
6735471 | Hill et al. | May 2004 | B2 |
6764498 | Mische | Jul 2004 | B2 |
6778854 | Puskas | Aug 2004 | B2 |
6788970 | Park et al. | Sep 2004 | B1 |
6798716 | Charych | Sep 2004 | B1 |
6802811 | Slepian | Oct 2004 | B1 |
6804561 | Stover | Oct 2004 | B2 |
6805998 | Jenson et al. | Oct 2004 | B2 |
6845267 | Harrison et al. | Jan 2005 | B2 |
RE38705 | Hill et al. | Feb 2005 | E |
6853858 | Shalev | Feb 2005 | B2 |
6865420 | Kroll | Mar 2005 | B1 |
6882883 | Condie et al. | Apr 2005 | B2 |
6904318 | Hill et al. | Jun 2005 | B2 |
6912419 | Hill et al. | Jun 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6937896 | Kroll | Aug 2005 | B1 |
6942622 | Turcott | Sep 2005 | B1 |
6985771 | Fischell et al. | Jan 2006 | B2 |
7010345 | Hill et al. | Mar 2006 | B2 |
7066891 | Stadler et al. | Jun 2006 | B2 |
7072720 | Puskas | Jul 2006 | B2 |
7092755 | Florio | Aug 2006 | B2 |
7123959 | Cates | Oct 2006 | B2 |
7194313 | Libbus | Mar 2007 | B2 |
7218964 | Hill et al. | May 2007 | B2 |
7225017 | Shelchuk | May 2007 | B1 |
7236821 | Cates et al. | Jun 2007 | B2 |
7245967 | Shelchuk | Jul 2007 | B1 |
7254440 | Kroll | Aug 2007 | B1 |
7260431 | Libbus et al. | Aug 2007 | B2 |
7272436 | Gill et al. | Sep 2007 | B2 |
7277761 | Shelchuk | Oct 2007 | B2 |
7280870 | Nurmikko et al. | Oct 2007 | B2 |
7294334 | Michal et al. | Nov 2007 | B1 |
7297114 | Gill et al. | Nov 2007 | B2 |
7299086 | McCabe et al. | Nov 2007 | B2 |
7300449 | Mische | Nov 2007 | B2 |
7305265 | Fukui | Dec 2007 | B2 |
7321793 | Ben Ezra et al. | Jan 2008 | B2 |
7340299 | Puskas | Mar 2008 | B2 |
7369892 | Ferek-Petric | May 2008 | B2 |
7403819 | Shelchuk et al. | Jul 2008 | B1 |
7415308 | Gerber et al. | Aug 2008 | B2 |
7460906 | Libbus | Dec 2008 | B2 |
7486991 | Libbus et al. | Feb 2009 | B2 |
7493161 | Libbus et al. | Feb 2009 | B2 |
7499748 | Moffitt et al. | Mar 2009 | B2 |
7509166 | Libbus | Mar 2009 | B2 |
7512438 | Fischell et al. | Mar 2009 | B2 |
7524287 | Bharmi | Apr 2009 | B2 |
7542800 | Libbus et al. | Jun 2009 | B2 |
7548780 | Libbus et al. | Jun 2009 | B2 |
7551958 | Libbus et al. | Jun 2009 | B2 |
7555341 | Moffitt et al. | Jun 2009 | B2 |
7558623 | Fischell et al. | Jul 2009 | B2 |
7561923 | Libbus et al. | Jul 2009 | B2 |
7570999 | Libbus et al. | Aug 2009 | B2 |
7577478 | Kroll et al. | Aug 2009 | B1 |
7584004 | Caparso et al. | Sep 2009 | B2 |
7587238 | Moffitt et al. | Sep 2009 | B2 |
7610092 | Cowan et al. | Oct 2009 | B2 |
7616990 | Chavan et al. | Nov 2009 | B2 |
7616997 | Kieval et al. | Nov 2009 | B2 |
7617003 | Caparso et al. | Nov 2009 | B2 |
7643875 | Hiel, Jr. et al. | Jan 2010 | B2 |
7647114 | Libbus | Jan 2010 | B2 |
7657312 | Pastore et al. | Feb 2010 | B2 |
7660628 | Libbus et al. | Feb 2010 | B2 |
7706884 | Libbus | Apr 2010 | B2 |
7711421 | Shafer et al. | May 2010 | B2 |
7734348 | Zhang et al. | Jun 2010 | B2 |
7769450 | Libbus et al. | Aug 2010 | B2 |
7783353 | Libbus et al. | Aug 2010 | B2 |
7840266 | Libbus | Nov 2010 | B2 |
7840278 | Puskas | Nov 2010 | B1 |
7869881 | Libbus et al. | Jan 2011 | B2 |
8000793 | Libbus | Aug 2011 | B2 |
8024050 | Libbus et al. | Sep 2011 | B2 |
8121693 | Libbus | Feb 2012 | B2 |
8126559 | Libbus | Feb 2012 | B2 |
8126560 | Scheiner et al. | Feb 2012 | B2 |
8126561 | Chavan et al. | Feb 2012 | B2 |
8131373 | Libbus | Mar 2012 | B2 |
8195289 | Heil, Jr. et al. | Jun 2012 | B2 |
8285389 | Libbus et al. | Oct 2012 | B2 |
20010000802 | Soykan et al. | May 2001 | A1 |
20010020136 | Sweeney et al. | Sep 2001 | A1 |
20020004670 | Florio et al. | Jan 2002 | A1 |
20020026221 | Hill et al. | Feb 2002 | A1 |
20020026222 | Schauerte et al. | Feb 2002 | A1 |
20020026228 | Schauerte et al. | Feb 2002 | A1 |
20020032468 | Hill et al. | Mar 2002 | A1 |
20020042637 | Stover | Apr 2002 | A1 |
20020058877 | Baumann et al. | May 2002 | A1 |
20020068875 | Schroeppel et al. | Jun 2002 | A1 |
20020072776 | Osorio et al. | Jun 2002 | A1 |
20020099328 | Scheiner et al. | Jul 2002 | A1 |
20020107553 | Hill et al. | Aug 2002 | A1 |
20020107557 | Edell et al. | Aug 2002 | A1 |
20020111661 | Cross et al. | Aug 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020120304 | Mest | Aug 2002 | A1 |
20020143369 | Hill et al. | Oct 2002 | A1 |
20020161410 | Kramer et al. | Oct 2002 | A1 |
20020165586 | Hill et al. | Nov 2002 | A1 |
20020183237 | Puskas | Dec 2002 | A1 |
20020183793 | Struble et al. | Dec 2002 | A1 |
20020198570 | Puskas | Dec 2002 | A1 |
20020198571 | Puskas | Dec 2002 | A1 |
20030003052 | Hampton | Jan 2003 | A1 |
20030004403 | Drinan et al. | Jan 2003 | A1 |
20030004549 | Hill et al. | Jan 2003 | A1 |
20030023175 | Arzbaecher et al. | Jan 2003 | A1 |
20030023279 | Spinelli et al. | Jan 2003 | A1 |
20030036773 | Whitehurst et al. | Feb 2003 | A1 |
20030040774 | Terry, Jr. et al. | Feb 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030045914 | Cohen et al. | Mar 2003 | A1 |
20030060848 | Keival et al. | Mar 2003 | A1 |
20030060854 | Zhu | Mar 2003 | A1 |
20030060857 | Perrson et al. | Mar 2003 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030069606 | Girouard et al. | Apr 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030078623 | Weinberg et al. | Apr 2003 | A1 |
20030078629 | Chen | Apr 2003 | A1 |
20030100924 | Foreman et al. | May 2003 | A1 |
20030105493 | Salo | Jun 2003 | A1 |
20030114905 | Kuzma | Jun 2003 | A1 |
20030132731 | Chung | Jul 2003 | A1 |
20030149354 | Bakharev | Aug 2003 | A1 |
20030149423 | Fischell | Aug 2003 | A1 |
20030149450 | Mayberg | Aug 2003 | A1 |
20030153952 | Auricchio et al. | Aug 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
20030181951 | Cates | Sep 2003 | A1 |
20030191402 | Arzbaecher et al. | Oct 2003 | A1 |
20030195578 | Perron et al. | Oct 2003 | A1 |
20030199958 | Zhang | Oct 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030212445 | Weinberg | Nov 2003 | A1 |
20030229380 | Adams et al. | Dec 2003 | A1 |
20040002739 | Cates et al. | Jan 2004 | A1 |
20040010303 | Bolea et al. | Jan 2004 | A1 |
20040019364 | Kieval et al. | Jan 2004 | A1 |
20040024422 | Hill et al. | Feb 2004 | A1 |
20040030362 | Hill et al. | Feb 2004 | A1 |
20040049235 | Deno et al. | Mar 2004 | A1 |
20040059238 | Fischell et al. | Mar 2004 | A1 |
20040059383 | Puskas | Mar 2004 | A1 |
20040093034 | Girouard et al. | May 2004 | A1 |
20040111118 | Hill et al. | Jun 2004 | A1 |
20040122477 | Whitehurst et al. | Jun 2004 | A1 |
20040138719 | Cho et al. | Jul 2004 | A1 |
20040138721 | Osorio et al. | Jul 2004 | A1 |
20040172074 | Yoshihito | Sep 2004 | A1 |
20040172075 | Shafer et al. | Sep 2004 | A1 |
20040186517 | Hill et al. | Sep 2004 | A1 |
20040186531 | Jahns et al. | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040199209 | Hill et al. | Oct 2004 | A1 |
20040199210 | Shelchuk | Oct 2004 | A1 |
20040215288 | Lee et al. | Oct 2004 | A1 |
20040215289 | Fukui | Oct 2004 | A1 |
20040220621 | Zhou et al. | Nov 2004 | A1 |
20040254616 | Rossing et al. | Dec 2004 | A1 |
20050018784 | Kurobe et al. | Jan 2005 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050043639 | Fischell | Feb 2005 | A1 |
20050043675 | Pastore et al. | Feb 2005 | A1 |
20050055060 | Koh et al. | Mar 2005 | A1 |
20050065445 | Arzbaecher et al. | Mar 2005 | A1 |
20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050075673 | Warkentin et al. | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050085736 | Ambrose et al. | Apr 2005 | A1 |
20050085864 | Schulman et al. | Apr 2005 | A1 |
20050096705 | Pastore et al. | May 2005 | A1 |
20050096707 | Hill et al. | May 2005 | A1 |
20050131467 | Boveja | Jun 2005 | A1 |
20050137483 | Fischell et al. | Jun 2005 | A1 |
20050143412 | Puskas | Jun 2005 | A1 |
20050143779 | Libbus | Jun 2005 | A1 |
20050143785 | Libbus | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050149126 | Libbus | Jul 2005 | A1 |
20050149127 | Libbus | Jul 2005 | A1 |
20050149128 | Heil et al. | Jul 2005 | A1 |
20050149129 | Libbus et al. | Jul 2005 | A1 |
20050149130 | Libbus | Jul 2005 | A1 |
20050149131 | Libbus et al. | Jul 2005 | A1 |
20050149132 | Libbus | Jul 2005 | A1 |
20050149133 | Libbus et al. | Jul 2005 | A1 |
20050149143 | Libbus et al. | Jul 2005 | A1 |
20050149155 | Scheiner et al. | Jul 2005 | A1 |
20050149156 | Libbus et al. | Jul 2005 | A1 |
20050187584 | Denker et al. | Aug 2005 | A1 |
20050187586 | David et al. | Aug 2005 | A1 |
20050197600 | Schuler et al. | Sep 2005 | A1 |
20050197675 | David et al. | Sep 2005 | A1 |
20050251216 | Hill et al. | Nov 2005 | A1 |
20050256417 | Fischell et al. | Nov 2005 | A1 |
20050261741 | Libbus et al. | Nov 2005 | A1 |
20060079945 | Libbus | Apr 2006 | A1 |
20060106429 | Libbus et al. | May 2006 | A1 |
20060116737 | Libbus | Jun 2006 | A1 |
20060122675 | Libbus et al. | Jun 2006 | A1 |
20060217772 | Libbus et al. | Sep 2006 | A1 |
20060229677 | Moffitt et al. | Oct 2006 | A1 |
20060253044 | Zhang | Nov 2006 | A1 |
20060259107 | Caparso et al. | Nov 2006 | A1 |
20060265020 | Fischell et al. | Nov 2006 | A1 |
20060271108 | Libbus et al. | Nov 2006 | A1 |
20060271115 | Ben-Ezra et al. | Nov 2006 | A1 |
20060271118 | Libbus et al. | Nov 2006 | A1 |
20060282131 | Caparso et al. | Dec 2006 | A1 |
20070021797 | Kieval et al. | Jan 2007 | A1 |
20070038259 | Kieval et al. | Feb 2007 | A1 |
20070038262 | Kieval et al. | Feb 2007 | A1 |
20070093720 | Fischell et al. | Apr 2007 | A1 |
20070093875 | Chavan et al. | Apr 2007 | A1 |
20070191904 | Libbus et al. | Aug 2007 | A1 |
20070208263 | John et al. | Sep 2007 | A1 |
20070249944 | Fischell et al. | Oct 2007 | A1 |
20070249947 | Fischell et al. | Oct 2007 | A1 |
20070276453 | Hill et al. | Nov 2007 | A1 |
20070293775 | Fischell et al. | Dec 2007 | A1 |
20070293778 | Fischell et al. | Dec 2007 | A1 |
20080015657 | Haefner | Jan 2008 | A1 |
20080021507 | Libbus et al. | Jan 2008 | A1 |
20080058660 | Fischell et al. | Mar 2008 | A1 |
20080064973 | Fischell et al. | Mar 2008 | A1 |
20080086174 | Libbus et al. | Apr 2008 | A1 |
20080125843 | Ben-David et al. | May 2008 | A1 |
20080139954 | Day et al. | Jun 2008 | A1 |
20080147140 | Ternes et al. | Jun 2008 | A1 |
20080183091 | Fischell et al. | Jul 2008 | A1 |
20080188762 | John et al. | Aug 2008 | A1 |
20080188763 | John et al. | Aug 2008 | A1 |
20080200960 | Libbus | Aug 2008 | A1 |
20080228238 | Libbus | Sep 2008 | A1 |
20090048528 | Hopenfeld et al. | Feb 2009 | A1 |
20090048641 | Libbus | Feb 2009 | A1 |
20090076403 | Hopenfeld | Mar 2009 | A1 |
20090082682 | Fischell et al. | Mar 2009 | A1 |
20090132002 | Kieval | May 2009 | A1 |
20090143834 | Libbus | Jun 2009 | A1 |
20090143838 | Libbus et al. | Jun 2009 | A1 |
20090149900 | Moffitt et al. | Jun 2009 | A1 |
20090171228 | Fischell et al. | Jul 2009 | A1 |
20090192397 | Fischell et al. | Jul 2009 | A1 |
20090198294 | Rossing et al. | Aug 2009 | A1 |
20090216141 | Fischell et al. | Aug 2009 | A1 |
20100049275 | Chavan et al. | Feb 2010 | A1 |
20100076511 | Heil, Jr. et al. | Mar 2010 | A1 |
20100106226 | Libbus | Apr 2010 | A1 |
20100121399 | McCabe et al. | May 2010 | A1 |
20100125307 | Pastore et al. | May 2010 | A1 |
20100185255 | Libbus | Jul 2010 | A1 |
20100222832 | Zhang et al. | Sep 2010 | A1 |
20100228308 | Cowan et al. | Sep 2010 | A1 |
20100274321 | Libbus | Oct 2010 | A1 |
20100286740 | Libbus et al. | Nov 2010 | A1 |
20100298898 | Libbus | Nov 2010 | A1 |
20110082514 | Libbus et al. | Apr 2011 | A1 |
20110082537 | Moffitt et al. | Apr 2011 | A1 |
20110106216 | Libbus et al. | May 2011 | A1 |
20110295333 | Libbus | Dec 2011 | A1 |
20110319960 | Libbus et al. | Dec 2011 | A1 |
20120123495 | Libbus | May 2012 | A1 |
20120158090 | Chavan et al. | Jun 2012 | A1 |
20120165888 | Libbus | Jun 2012 | A1 |
20120239099 | Heil, Jr. et al. | Sep 2012 | A1 |
Number | Date | Country |
---|---|---|
0054138 | Jun 1982 | EP |
0467695 | Jan 1992 | EP |
0547734 | Jun 1993 | EP |
1050265 | Nov 2000 | EP |
1304135 | Apr 2003 | EP |
1486232 | Dec 2004 | EP |
1541193 | Jun 2005 | EP |
1706177 | Oct 2006 | EP |
1297991 | Nov 1972 | GB |
49015438 | Apr 1974 | JP |
05269210 | Oct 1993 | JP |
8-52121 | Feb 1996 | JP |
9225041 | Sep 1997 | JP |
2003503119 | Jan 2003 | JP |
2004173791 | Jun 2004 | JP |
2004526471 | Sep 2004 | JP |
2004533297 | Nov 2004 | JP |
2005519680 | Jul 2005 | JP |
2005521489 | Jul 2005 | JP |
5192414 | Aug 2011 | JP |
201220185 | Feb 2012 | JP |
WO-9216257 | Oct 1992 | WO |
WO-9407564 | Apr 1994 | WO |
WO-9639932 | Dec 1996 | WO |
WO-9713550 | Apr 1997 | WO |
WO-9733513 | Sep 1997 | WO |
WO-9740885 | Nov 1997 | WO |
WO-9407564 | Dec 1999 | WO |
WO-9965561 | Dec 1999 | WO |
WO-0007497 | Feb 2000 | WO |
WO-0100273 | Jan 2001 | WO |
WO-0124876 | Apr 2001 | WO |
WO-0130436 | May 2001 | WO |
WO-0176689 | Oct 2001 | WO |
WO-0226314 | Apr 2002 | WO |
WO-0226318 | Apr 2002 | WO |
WO-0226320 | Apr 2002 | WO |
WO-0234327 | May 2002 | WO |
WO-02085448 | Oct 2002 | WO |
WO-02096512 | Dec 2002 | WO |
WO-03076008 | Sep 2003 | WO |
WO-03082080 | Oct 2003 | WO |
WO-03082080 | Oct 2003 | WO |
WO-03082403 | Oct 2003 | WO |
WO-03099377 | Dec 2003 | WO |
WO-03105658 | Dec 2003 | WO |
WO-2004012814 | Feb 2004 | WO |
WO-2004084990 | Oct 2004 | WO |
WO-2004084993 | Oct 2004 | WO |
WO-2004103455 | Dec 2004 | WO |
WO-2004105637 | Dec 2004 | WO |
WO-2004105870 | Dec 2004 | WO |
WO-2004110549 | Dec 2004 | WO |
WO-2004110550 | Dec 2004 | WO |
WO-2005009535 | Feb 2005 | WO |
WO-2005018739 | Mar 2005 | WO |
WO-2005042091 | May 2005 | WO |
WO-2005053788 | Jun 2005 | WO |
WO-2005063332 | Jul 2005 | WO |
WO-2005065771 | Jul 2005 | WO |
WO-2005113066 | Dec 2005 | WO |
WO-2006031331 | Mar 2006 | WO |
WO-2006069215 | Jun 2006 | WO |
WO-20060110338 | Oct 2006 | WO |
WO-2006121929 | Nov 2006 | WO |
WO-2007050657 | May 2007 | WO |
WO-2008063396 | May 2008 | WO |
WO-2011146393 | Nov 2011 | WO |
Entry |
---|
US 8,315,702, 11/2012, Chavan et al. (withdrawn) |
“U.S. Appl. No. 10/079,056, Final Office Action mailed Sep. 1, 2005”, 7 pgs. |
“U.S. Appl. No. 10/079,056, Non Final Office Action mailed Feb. 27, 2004”, 6 pgs. |
“U.S. Appl. No. 10/079,056, Non Final Office Action mailed Mar. 24, 2005”, 5 pgs. |
“U.S. Appl. No. 10/079,056, Non Final Office Action mailed Apr. 14, 2006”, 5 pgs. |
“U.S. Appl. No. 10/079,056, Non Final Office Action mailed Sep. 9, 2004”, 11 pgs. |
“U.S. Appl. No. 10/079,056, Notice of Allowance mailed Feb. 20, 2007”, 4 pgs. |
“U.S. Appl. No. 10/079,056, Response filed Feb. 1, 2006 to Final Office Action mailed Sep. 1, 2005”, 31 pgs. |
“U.S. Appl. No. 10/079,056, Response filed Jun. 21, 2005 to Non Final Office Action mailed Mar. 24, 2005”, 28 pgs. |
“U.S. Appl. No. 10/079,056, Response filed Jun. 22, 2004 to Non Final Office Action mailed Feb. 27, 2004”, 5 pgs. |
“U.S. Appl. No. 10/079,056, Response filed Oct. 12, 2006 to Non Final Office Action mailed Apr. 14, 2006”, 32 pgs. |
“U.S. Appl. No. 10/079,056, Response filed Dec. 22, 2004 to Non Final Office Action mailed Sep. 9, 2004”, 30 pgs. |
“U.S. Appl. No. 10/700,368, Notice of Allowance mailed Sep. 15, 2009”, 7 pgs. |
“U.S. Appl. No. 10/700,368, Response filed Jul. 20, 2009 to Non Final Office Action mailed Feb. 25, 2009”, 11 pgs. |
“U.S. Appl. No. 10/745,921, Appeal Brief filed Jul. 3, 2007”, 37 pgs. |
“U.S. Appl. No. 10/745,921, Decision on Appeal mailed Sep. 3, 2008”, 18 pgs. |
“U.S. Appl. No. 10/745,921, Examiner Interview Summary mailed Mar. 24, 2010”, 3 pgs. |
“U.S. Appl. No. 10/745,921, Final Office Action mailed Jan. 14, 2010”, 16 pgs. |
“U.S. Appl. No. 10/745,921, Non-Final Office Action mailed Jul. 27, 2009”, 15 pgs. |
“U.S. Appl. No. 10/745,921, Notice of Allowance mailed Sep. 7, 2010”, 6 pgs. |
“U.S. Appl. No. 10/745,921, Notification mailed Jun. 5, 2007”, 2 pgs. |
“U.S. Appl. No. 10/745,921, Response filed Feb. 21, 2006 to Restriction Requirement mailed Jan. 19, 2006”, 15 pgs. |
“U.S. Appl. No. 10/745,921, Response filed May 6, 2009 to Restriction Requirement mailed Jan. 6, 2009”, 12 pgs. |
“U.S. Appl. No. 10/745,921, Response filed Jun. 14, 2010 to Final Office Action mailed Jan. 14, 2010”, 16 pgs. |
“U.S. Appl. No. 10/745,921, Response filed Oct. 27, 2009 to Non Final Office Action mailed Jul. 27, 2009”, 16 pgs. |
“U.S. Appl. No. 10/745,921, Restriction Requirement mailed Jan. 6, 2009”, 9 pgs. |
“U.S. Appl. No. 10/745,921, Restriction Requirement mailed Jan. 19, 2006”, 5 pgs. |
“U.S. Appl. No. 10/745,921, Supplemental Notice of Allowability mailed Nov. 1, 2010”, 4 pgs. |
“U.S. Appl. No. 10/746,134, Notice of Allowance mailed Aug. 10, 2009”, 7 pgs. |
“U.S. Appl. No. 10/746,134, Response filed Jul. 6, 2009 to Non-Final Office Action mailed Feb. 6, 2009”, 16 pgs. |
“U.S. Appl. No. 10/746,134, Supplemental Notice of Allowability mailed Aug. 31, 2009”, 5 pgs. |
“U.S. Appl. No. 10/746,135, Appeal Brief mailed May 10, 2010”, 43 pgs. |
“U.S. Appl. No. 10/746,135, Decision on Pre-Appeal Brief Request mailed Mar. 10, 2010”, 2 pgs. |
“U.S. Appl. No. 10/746,135, Examiner Interview Summary mailed Feb. 6, 2009”, 8 pgs. |
“U.S. Appl. No. 10/746,135, Examiner's Answer to Appeal Brief mailed Jul. 22, 2010”, 17 pgs. |
“U.S. Appl. No. 10/746,135, Final Office Action mailed Mar. 18, 2008”, 16 pgs. |
“U.S. Appl. No. 10/746,135, Final Office Action mailed Jul. 22, 2009”, 14 pgs. |
“U.S. Appl. No. 10/746,135, Non Final Office Action mailed Feb. 12, 2007”, 21 pgs. |
“U.S. Appl. No. 10/746,135, Non Final Office Action mailed Jul. 19, 2007”, 27 pgs. |
“U.S. Appl. No. 10/746,135, Non Final Office Action mailed Aug. 1, 2006”, 33 pgs. |
“U.S. Appl. No. 10/746,135, Non-Final Office Action mailed Sep. 30, 2008”, 18 pgs. |
“U.S. Appl. No. 10/746,135, Pre-Appeal Brief Request filed Dec. 21, 2009”, 5 pgs. |
“U.S. Appl. No. 10/746,135, Preliminary Amendment filed Feb. 9, 2004”, 5 pgs. |
“U.S. Appl. No. 10/746,135, Reply Brief filed Sep. 22, 2010”, 9 pgs. |
“U.S. Appl. No. 10/746,135, Response filed Mar. 30, 2009 to Non Final Office Action mailed Sep. 30, 2008”, 26 pgs. |
“U.S. Appl. No. 10/746,135, Response filed May 2, 2007 to Non Final Office Action mailed Feb. 12, 2007”, 19 pgs. |
“U.S. Appl. No. 10/746,135, Response filed Jul. 7, 2006 to Restriction Requirement mailed Jun. 9, 2006”, 9 pgs. |
“U.S. Appl. No. 10/746,135, Response filed Jul. 17, 2008 to Final Office Action mailed Mar. 18, 2008”, 20 pgs. |
“U.S. Appl. No. 10/746,135, Response filed Nov. 21, 2006 to Non Final Office Action mailed Aug. 1, 2006”, 17 pgs. |
“U.S. Appl. No. 10/746,135, Response filed Dec. 19, 2007 to Non-Final Office Action mailed Jul. 19, 2007”, 22 pgs. |
“U.S. Appl. No. 10/746,135, Restriction Requirement mailed Jun. 9, 2006”, 5 pgs. |
“U.S. Appl. No. 10/746,135, Supplemental Preliminary Amendment filed Apr. 11, 2005”, 9 pgs. |
“U.S. Appl. No. 10/746,135, Supplemental Preliminary Amendment filed Sep. 23, 2004”, 7 pgs. |
“U.S. Appl. No. 10/746,844, Advisory Action mailed Nov. 16, 2009”, 3 pgs. |
“U.S. Appl. No. 10/746,844, Final Office Action mailed Aug. 17, 2009”, 9 pgs. |
“U.S. Appl. No. 10/746,844, Notice of Allowance mailed Dec. 18, 2009”, 5 pgs. |
“U.S. Appl. No. 10/746,844, Response filed May 11, 2009 to Non Final Office Action mailed Feb. 10, 2009”, 20 pgs. |
“U.S. Appl. No. 10/746,844, Response filed Oct. 19, 2009 to Final Office Action mailed Aug. 17, 2009”, 9 pgs. |
“U.S. Appl. No. 10/746,844, Response filed Nov. 16, 2007 to Restriction Requirement mailed Oct. 17, 2007”, 17 pgs. |
“U.S. Appl. No. 10/746,844, Restriction Requirement mailed Oct. 17, 2007”, 9 pgs. |
“U.S. Appl. No. 10/746,847, Examiner Interview Summary mailed Jun. 16, 2009”, 9 pgs. |
“U.S. Appl. No. 10/746,847, Final Office Action mailed Oct. 1, 2009”, 10 pgs. |
“U.S. Appl. No. 10/746,847, Supplemental Amendment filed Jun. 22, 2009”, 10 pgs. |
“U.S. Appl. No. 10/746,852, Appeal Brief filed Dec. 22, 2008”, 26 pgs. |
“U.S. Appl. No. 10/746,852, Decision on Pre-Appeal Brief mailed Aug. 22, 2008”, 2 pgs. |
“U.S. Appl. No. 10/746,852, Examiner's Answer mailed Mar. 13, 2009”, 17 pgs. |
“U.S. Appl. No. 10/746,852, Final Office Action mailed Jul. 27, 2011”, 7 pgs. |
“U.S. Appl. No. 10/746,852, Notice of Allowance mailed Oct. 18, 2011”, 8 pgs. |
“U.S. Appl. No. 10/746,852, Pre-Appeal Brief Request filed Jul. 18, 2008”, 5 pgs. |
“U.S. Appl. No. 10/746,852, Response filed Sep. 7, 2011 to Final Office Action mailed Jul. 27, 2011”, 8 pgs. |
“U.S. Appl. No. 10/746,861, Advisory Action mailed Nov. 12, 2010”, 3 pgs. |
“U.S. Appl. No. 10/746,861, Decision on Pre-Appeal Brief mailed Nov. 21, 2008”, 2 pgs. |
“U.S. Appl. No. 10/746,861, Examiner Interview Summary mailed Mar. 26, 2010”, 3 pgs. |
“U.S. Appl. No. 10/746,861, Final Office Action mailed Jul. 7, 2010”, 12 pgs. |
“U.S. Appl. No. 10/746,861, Non-Final Office Action mailed Nov. 24, 2009”, 8 pgs. |
“U.S. Appl. No. 10/746,861, Notice of Allowance mailed May 13, 2011”, 7 pgs. |
“U.S. Appl. No. 10/746,861, Response filed Mar. 24, 2010 to Non-Final Office Action mailed Nov. 24, 2009”, 14 pgs. |
“U.S. Appl. No. 10/746,861, Response filed Jul. 1, 2009 to Non Final Office Action mailed Feb. 2, 2009”, 9 pgs. |
“U.S. Appl. No. 10/746,861, Response filed Sep. 7, 2010 to Final Office Action mailed Jul. 7, 2010”, 13 pgs. |
“U.S. Appl. No. 10/939,544, Examiner Interview Summary mailed Sep. 3, 2008”, 14 pgs. |
“U.S. Appl. No. 10/939,544, Examiner Interview Summary mailed Nov. 6, 2006”, 2 pgs. |
“U.S. Appl. No. 10/939,544, Notice of Allowance mailed Sep. 3, 2009”, 12 pgs. |
“U.S. Appl. No. 10/939,544, Response filed Aug. 5, 2009 to Final Office Action mailed Mar. 5, 2009”, 16 pgs. |
“U.S. Appl. No. 11/103,245, Non-Final Office Action mailed Jan. 11, 2008”, 9 pgs. |
“U.S. Appl. No. 11/103,245, Notice of Allowance mailed Oct. 20, 2008”, 4 pgs. |
“U.S. Appl. No. 11/103,245, Response filed Jul. 11, 2008 to Non-Final Office Action mailed Jan. 11, 2008”, 14 pgs. |
“U.S. Appl. No. 11/103,245, Response filed Oct. 17, 2007 to Restriction Requirement mailed Sep. 18, 2007”, 7 pgs. |
“U.S. Appl. No. 11/103,245, Restriction Requirement mailed Sep. 18, 2007”, 6 pgs. |
“U.S. Appl. No. 11/130,022, Non-Final Office Action mailed Jan. 28, 2009”, 6 pgs. |
“U.S. Appl. No. 11/130,022, Non-Final Office Action mailed May 15, 2008”, 9 pgs. |
“U.S. Appl. No. 11/130,022, Notice of Allowance mailed Jul. 21, 2009”, 6 pgs. |
“U.S. Appl. No. 11/130,022, Response filed Apr. 28, 2009 to Non Final Office Action mailed Jan. 28, 2009”, 11 pgs. |
“U.S. Appl. No. 11/130,022, Response filed Aug. 15, 2008 to Non-Final Office Action mailed May 15, 2008”, 18 pgs. |
“U.S. Appl. No. 11/256,907, Final Office Action mailed Mar. 27, 2009”, 8 pgs. |
“U.S. Appl. No. 11/256,907, Non-Final Office Action mailed Jul. 8, 2008”, 6 pgs. |
“U.S. Appl. No. 11/256,907, Notice of Allowance mailed Jul. 1, 2009”, 5 pgs. |
“U.S. Appl. No. 11/256,907, Response and Preliminary Amendment filed Apr. 21, 2008 to Restriction Requirement mailed Mar. 21, 2008”, 9 pgs. |
“U.S. Appl. No. 11/256,907, Response filed May 27, 2009 to Final Office Action mailed Mar. 27, 2009”, 10 pgs. |
“U.S. Appl. No. 11/256,907, Response filed Nov. 7, 2008 to Non-Final Office Action mailed Jul. 8, 2008”, 12 pgs. |
“U.S. Appl. No. 11/256,907, Restriction Requirement mailed Mar. 21, 2008”, 11 pgs. |
“U.S. Appl. No. 11/312,178, Notice of Allowance mailed Apr. 3, 2009”, 6 pgs. |
“U.S. Appl. No. 11/482,357, Non Final Office Action mailed Jul. 17, 2009”, 12 pgs. |
“U.S. Appl. No. 11/482,357, Notice of Allowance mailed Mar. 25, 2010”, 4 pgs. |
“U.S. Appl. No. 11/482,357, Preliminary Statement mailed Oct. 30, 2006”, 3 pgs. |
“U.S. Appl. No. 11/482,357, Response filed Dec. 17, 2009 to Non Final Office Action mailed Jul. 17, 2009”, 13 pgs. |
“U.S. Appl. No. 11/558,083, 312 Amendment filed Jul. 8, 2010”, 10 pgs. |
“U.S. Appl. No. 11/558,083, Non-Final Office Action mailed Jun. 26, 2009”, 17 pgs. |
“U.S. Appl. No. 11/558,083, Notice of Allowance mailed Apr. 8, 2010”, 7 pgs. |
“U.S. Appl. No. 11/558,083, PTO Response to 312 Amendment mailed Jul. 21, 2010”, 2 pgs. |
“U.S. Appl. No. 11/558,083, Response filed Dec. 22, 2009 to Non-Final Office Action mailed Jun. 26, 2009”, 15 pgs. |
“U.S. Appl. No. 11/621,194, Final Office Action mailed May 19, 2010”, 8 pgs. |
“U.S. Appl. No. 11/621,194, Non-Final Office Action mailed Oct. 1, 2009”, 22 pgs. |
“U.S. Appl. No. 11/621,194, Response filed Mar. 1, 2010 to Non Final Office Action mailed Oct. 1, 2009”, 11 pgs. |
“U.S. Appl. No. 11/621,194, Response filed Aug. 19, 2010 to Final Office Action mailed May 19, 2010”, 8 pgs. |
“U.S. Appl. No. 12/126,182, Non-Final Office Action mailed Jul. 23, 2010”, 9 pgs. |
“U.S. Appl. No. 12/126,182, Notice of Allowance mailed Apr. 18, 2011”, 12 pgs. |
“U.S. Appl. No. 12/126,182, Response filed Oct. 25, 2010 to Non Final Office Action mailed Jul. 23, 2010”, 12 pgs. |
“U.S. Appl. No. 12/257,079, Final Office Action mailed May 10, 2011”, 11 pgs. |
“U.S. Appl. No. 12/257,079, Non-Final Office Action mailed Oct. 1, 2010”, 10 pgs. |
“U.S. Appl. No. 12/257,079, Notice of Allowance mailed Oct. 12, 2011”, 8 pgs. |
“U.S. Appl. No. 12/257,079, Response filed Mar. 1, 2011 to Non Final Office Action mailed Oct. 1, 2010”, 9 pgs. |
“U.S. Appl. No. 12/257,079, Response filed Aug. 10, 2011 to Final Office Action mailed May 10, 2011”, 9 pgs. |
“U.S. Appl. No. 12/257,079, Response filed Sep. 7, 2010 to Restriction Requirement mailed Aug. 5, 2010”, 9 pgs. |
“U.S. Appl. No. 12/257,079, Restriction Requirement mailed Jun. 5, 2010”, 5 pgs. |
“U.S. Appl. No. 12/257,079, Restriction Requirement mailed Aug. 5, 2010”, 5 pgs. |
“U.S. Appl. No. 12/321,949, Final Office Action mailed Dec. 16, 2010”, 8 pgs. |
“U.S. Appl. No. 12/321,949, Non-Final Office Action mailed Jul. 29, 2010”, 8 pgs. |
“U.S. Appl. No. 12/321,949, Response filed Mar. 9. 2011 to Final Office Action mailed Dec. 16, 2010”, 8 pgs. |
“U.S. Appl. No. 12/321,949, Response filed Jun. 3, 2010 to Restriction Requirement mailed May 3, 2010”, 11 pgs. |
“U.S. Appl. No. 12/321,949, Response filed Oct. 29, 2010 to Non Final Office Action mailed Jul. 29, 2010”, 9 pgs. |
“U.S. Appl. No. 12/321,949, Restriction Requirement mailed May 3, 2010”, 7 pgs. |
“U.S. Appl. No. 12/368,842, Advisory Action mailed Nov. 9, 2011”, 3 pgs. |
“U.S. Appl. No. 12/368,842, Decision on Pre Appeal Brief mailed Jan. 12, 2012”, 3pgs. |
“U.S. Appl. No. 12/368,842, Final Office Action mailed Jul. 19, 2011”, 13 pgs. |
“U.S. Appl. No. 12/368,842, Non Final Office Action mailed Dec. 28, 2010”, 10 pgs. |
“U.S. Appl. No. 12/368,842, Pre-Appeal Brief Request Nov. 21, 2011”, 5 pgs. |
“U.S. Appl. No. 12/368,842, Response filed Mar. 28, 2011 to Non Final Office Action mailed Dec. 28, 2010”, 10 pgs. |
“U.S. Appl. No. 12/368,842, Response filed Oct. 19, 2011 to Final Office Action mailed Jul. 19, 2011”, 11 pgs. |
“U.S. Appl. No. 12/368,842, Response filed Nov. 1, 2010 to Restriction Requirement mailed Sep. 30, 2010”, 9 pgs. |
“U.S. Appl. No. 12/368,842, Restriction Requirement mailed Sep. 30, 2010”, 6 pgs. |
“U.S. Appl. No. 12/371,153, Final Office Action Mailed Dec. 17, 2011”, 7 pgs. |
“U.S. Appl. No. 12/371,153, Non Final Office Action mailed Apr. 12, 2012”, 10 pgs. |
“U.S. Appl. No. 12/371,153, Response filed Mar. 14, 2012 to Final Office Action mailed Dec. 14, 2011”, 8 pgs. |
“U.S. Appl. No. 12/613,094, Non Final Office Action mailed Jul. 18, 2011”, 6 pgs. |
“U.S. Appl. No. 12/613,094, Notice of Allowance mailed Oct. 26, 2011”, 5 pgs. |
“U.S. Appl. No. 12/613,094, Response filed Oct. 18, 2011 to Non Final Office Action mailed Jul. 18, 2011”, 10 pgs. |
“U.S. Appl. No. 12/627,562 , Response filed Jul. 23, 2012 to Final Office Action mailed Nov. 21, 2011”, 9 pgs. |
“U.S. Appl. No. 12/627,562, Examiner Interview Summary mailed Jul. 25, 2012”, 3 pgs. |
“U.S. Appl. No. 12/627,562, Final Office Action mailed Nov. 21, 2011”, 11 pgs. |
“U.S. Appl. No. 12/627,562, Non Final Office Action mailed Jun. 15, 2011”, 10 pgs. |
“U.S. Appl. No. 12/627,562, Notice of Allowance mailed Feb. 6, 2012”, 5 pgs. |
“U.S. Appl. No. 12/627,562. Response filed Oct. 14, 2011 to Non Final Office Action mailed Jun. 15, 2011”, 15 pgs. |
“U.S. Appl. No. 12/693,660, Final Office Action mailed Apr. 21, 2011”, 10 pgs. |
“U.S. Appl. No. 12/693,660, Non Final Action mailed Jan. 11, 2012”, 9 pgs. |
“U.S. Appl. No. 12/693,660, Non-Final Office Action mailed Oct. 28, 2010”, 8 pgs. |
“U.S. Appl. No. 12/693,660, Notice of Allowance mailed Sep. 27, 2011”, 7 pgs. |
“U.S. Appl. No. 12/693,660, Response filed Feb. 28, 2011 to Non Final Office Action mailed Oct. 28, 2010”, 9 pgs. |
“U.S. Appl. No. 12/693,660, Response filed Sep. 2, 2010 to Restriction Requirement mailed Aug. 2, 2010”, 7 pgs. |
“U.S. Appl. No. 12/693,660, Restriction Requirement mailed Aug. 2, 2010”, 8 pgs. |
“U.S. Appl. No. 12/749,939, Notice of Allowance mailed Oct. 25, 2011”, 10 pgs. |
“U.S. Appl. No. 12/749,939, Response filed Aug. 22, 2011 to Restriction Requirement mailed Mar. 21, 2011”, 13 pgs. |
“U.S. Appl. No. 12/749,939, Response to Rule 312 Communication mailed Feb. 3, 2012”. |
“U.S. Appl. No. 12/749,939, Restriction Requirement mailed Mar. 21, 2011”, 14 pgs. |
“U.S. Appl. No. 12/850,245, Non Final Office Action mailed Dec. 15, 2011”, 26 pgs. |
“U.S. Appl. No. 12/850,245, Restriction Requirement mailed Oct. 19, 2011”, 11 pgs. |
“U.S. Appl. No. 13/402,196, Notice of Allowance mailed Jul. 16, 2012”, 8 pgs. |
“European Application Serial No. 05787559.3, Response filed Jul. 23, 2009 to Communication mailed Jan. 29, 2009”, 12 pgs. |
“European Application Serial No. 06740184.4, Response filed Nov. 28, 2011 to Office Action mailed May 18, 2011”, 10 pgs. |
“European Application Serial No. 06827323.4, Communication mailed Jun. 2, 2009”, 2 pgs. |
“European Application Serial No. 06827323.4, Response filed Apr. 24, 2009 to Communication mailed Nov. 12, 2008”, 6 pgs. |
“European Application Serial No. 06827323.4, Summons to Attend Oral Proceedings mailed May 19, 2010”, 3 pgs. |
“European Application Serial No. 06827323.4, Written Submissions filed Sep. 23, 2010”, 4 pgs. |
“European Application Serial No. 06836504.8, Communication mailed Jun. 2, 2008”, 2 pgs. |
“European Application Serial No. 06836504.8, Communication mailed Oct. 9, 2008”, 5 pgs. |
“European Application Serial No. 06836504.8, Decision to Refuse a European Patent Application mailed Jun. 22, 2010”, 31 pgs. |
“European Application Serial No. 06836504.8, Grounds of Appeal Filed/ Written Statements Filed Oct. 25, 2010”, 40 pgs. |
“European Application Serial No. 06836504.8, Response filed Feb. 19, 2009 to Communication mailed Oct. 9, 2008”, 7 pgs. |
“European Application Serial No. 06836504.8, Summons to Attend Oral Proceedings mailed Mar. 9, 2010”, 11 pgs. |
“European Application Serial No. 06836504.8, Summons to Attend Oral Proceedings mailed Nov. 13, 2009”, 6 pgs. |
“European Application Serial No. 07861710.7, Office Action mailed Aug. 23, 2010”, 3 pgs. |
“European Application Serial No. 07861710.7, Response filed Feb. 28, 2011 to Non Final Office Action mailed Aug. 23, 2010”, 15 pgs. |
“European Application Serial No. 10181222.0, European Search mailed May 20, 2011”, 7 pgs. |
“European Application Serial No. 10181222.0, Response filed Dec. 21, 2011 to Extended Search Report mailed May 20, 2011”, 4 pgs. |
“European Application Serial No. 10181314.5, European Search Report mailed May 26, 2011”, 7 pgs. |
“European Application Serial No. 10181314.5, Response filed Dec. 21, 2011 to Extended Search Report mailed May 26, 2011”, 4 pgs. |
“European Application Serial No. 06740184.4, Office Action mailed May 18, 2011”, 6 pgs. |
“International Application No. PCT/US2004/036606, Written Opinion dated Mar. 10, 2005”, 5 pgs. |
“International Application Serial No. PCT/ US2011/036644, International Search Report mailed Dec. 29, 2011”, 6 pgs. |
“International Application Serial No. PCT/ US2011/036644, Written Opinion mailed Dec. 19, 2011”, 11 pgs. |
“International Application Serial No. PCT/US2007/023288, International Search Report and Written Opinion mailed Apr. 23, 2008”, 13 pgs. |
“International Application Serial No. PCT/US2011/036644, Invitation to Pay Additional Fees mailed Aug. 29, 2011”, 8 pgs. |
“International Search Report and Written Opinion for Application No. PCT/US2006/011882, date mailed Aug. 2, 2006”, 13 Pages. |
“International Search Report and Written Opinion for Application No. PCT/US2006/041569”, (Mar. 7, 2007), 14 pgs. |
“Japanese Application No. 2008506496—Office Action Response—Jan. 31, 2012”, 11 Pgs. |
“Japanese Application Serial No. 2006-547356, Notice of Allowance mailed May 18, 2011”, 3 Pgs. |
“Japanese Application Serial No. 2006-547356, Office Action mailed Jul. 6, 2010”, wtih English translation, 7 pgs. |
“Japanese Application Serial No. 2006-547356, Office Action Response filed Oct. 5, 2010”, (w/ English Translation of Amended Claims), 68 pgs. |
“Japanese Application Serial No. 2006-547356, Response filed Apr. 20, 2011 to Office Action mailed Feb. 1, 2011”, 11 pgs. |
“Japanese Application Serial No. 2006-547356,Office Action mailed Feb. 1, 2011”, (w/ English Translation), 15 pgs. |
“Japanese Application Serial No. 2006-547492, Notice of Allowance dated Oct. 19, 2010”, (w/ English Translation), 2 pgs. |
“Japanese Application Serial No. 2006-547492, Office Action mailed Jun. 8, 2010”, (w/ English Translation), 5 pgs. |
“Japanese Application Serial No. 2006-547492, Response filed Oct. 6, 2010 to Office Action dated Jun. 8, 2010”, (w/ English Translation of Amended Claims), 14 pgs. |
“Japanese Application Serial No. 2007-531174, Office Action Response mailed Oct. 28, 2011”, 8 pgs. |
“Japanese Application Serial No. 2008-506496, Office Action mailed Oct. 31, 2011”, (w/ English Translation), 14 pgs. |
“Japanese Application Serial No. 2008-536619, Office Action mailed Nov. 28, 2011”, 4 pgs. |
“Japanese Application Serial No. 2008-536619, Response filed Feb. 28, 2012 to Office Action mailed Nov. 28, 2011”, 12 pgs. |
“Japanese Application Serial No. 2008-547225, Office Action mailed Nov. 29, 2011”, W/ English Translation, 4 pgs. |
“Japanese Application Serial No. 2007-531174, Office Action mailed Apr. 28, 2011”, 3. |
“Structural Remodeling of Cardiac Myocytes in Hypertrophy and Progression to Failure; and, on Atrial Remodeling and Drug Treatment of Atrial Fibrillation”, in Cardia Remodeling and Failure, in Section II. Remodeling and Heart Failure, Singal, et al., editors; Kluwer Academic Publishers, (2003), 183-93; 319-30. |
Andersen, H, et al., “Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome”, Lancet, 350(9086), (Oct. 25, 1997), 1210-6. |
Arnaud, Claire, et al., “iNOS is a mediator of the heat stress-induced preconditioning against myocardial infarction in vivo in the rat”, Cardiovascular Research, 58, (2003), 118-125. |
Benchimol, A, et al., “Cardiac hemodynamics during stimulation of the right atrium, right ventricle, and left ventricle in normal and abnormal hearts”, Circulation, 33(6), (Jun. 1966), 933-44. |
Bevan, J A, et al., “Postganglionic sympathetic delay in vascular smooth muscle”, Journal of Pharmacology & Experimental Therapeutics, 152(2), (May 1966), 221-30. |
Bevan, J A, et al., “Sympathetic nerve-free vascular muscle”, Journal of Pharmacology & Experimental Therapeutics, 157(1), (Jul. 1967), 117-24. |
Bilgutay, A M, et al., “A new concept in the treatment of hypertension utilizing an implantable electronic device: ”Baropacer“”, Trans Am Soc Artif Intern Organs., 10, (1964), 387-395. |
Bilgutay, A M, et al., “Vagal tuning for the control of supraventricular arrhythmias”, Surgical Forum, 16, (1965), 151-3. |
Bilgutay, A. M, et al., “Vagal tuning. A new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure”, Journal of Thoracic and Cardiovascular Surgery, 56(1), (Jul. 1968), 71-82. |
Borst, C, et al., “Optimal frequency of carotid sinus nerve stimulation in treatment of angina pectoris”, Cardiovascular Research, 8(5), (Sep. 1974), 674-80. |
Braunwald, E, et al., “Carotid sinus nerve stimulation in the treatment of angina pectoris and supraventricular tachycardia”, California Medicine, 112(3), (Mar. 1970), 41-50. |
Braunwald, E, et al., “Relief of angina pectoris by electrical stimulation of the carotid-sinus nerves”, New England Journal of Medicine, 277(24), (Dec. 14, 1967), 1278-83. |
Brunner, Friedrich, “Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase”, Cardiovascular Research, 57, (2003), 55-62. |
Burns, Brent E., “Fabrication Technology for a Chronic In-Vivo Pressure Sensor”, 1984 International Electron Devices Meeting Technical Digest, (1984), 210-212. |
Caparso, Anthony, “System for Selective Activation of a Nerve Trunk Using a Transvascular Reshaping Lead”, U.S. Appl. No. 11/130,022 filed May 16, 2005, 33 pgs. |
Carr, William N., “Integrated Pressure Sensor With Remote Power Source and Remote Readout”, The 8th International Conference on Solid-State Sensors and Actuators and Eurosensors IX, Digest of Technical Papers, Stockholm, Sweden, (Jun. 25-29, 1995), 624-627. |
Cates, Adam W, et al., “Chronically-Implanted Device for Sensing and Therapy”, U.S. Appl. No. 10/079,056, filed Feb. 19, 2002, 88. |
Chapleau, M. W., et al., “Contrasting effects of static and pulsatile pressure on carotid baroreceptor activity in dogs”, Circulation, vol. 61, No. 5, (Nov. 1987), 648-658. |
Chapleau, Mark W., “Pulsatile activation of baroreceptors causes central facilitation of baroreflex”, American Journal Physiol Heart Circ Physiol, (Jun. 1989), 256: H1735 - 1741. |
Chau, Hin-Leung, “An Ultraminiature Solid-State Pressure Sensor for a Cardiovascular Catheter”, IEEE Transactions on Electron Devices, (Dec. 1988), 2355-2362. |
Chavan, Abhi, et al., “Implantable and Rechargeable Neural Stimulator”, U.S. Appl. No. 11/256,907, filed Oct. 24, 2005, 35 pgs. |
Coleridge, J C, et al., “Relationship between pulmonary arterial pressure and impulse activity in pulmonary arterial baroreceptor fibres”, Journal of Physiology, 158, (Sep. 1961), 197-205. |
Coleridge, J C, et al., “The distribution, connexions and histology of baroreceptors in the pulmonary artery, with some observations on the sensory innervation of the ductus arteriosus”, Journal of Physiology, 156, (May 1961), 591-602. |
Cooper, Terry B, et al., “Neural effects on sinus rate and atrioventricular conduction produced by electrical stimulation from a transvenous electrode catheter in the canine right pulmonary artery”, Circulation Research, vol. 46, No. 1, (Jan. 1980), 48-57. |
Courtice, G P, et al., “Effect of frequency and impulse pattern on the non-cholinergic cardiac response to vagal stimulation in the toad, Bufo marinus”, Journal of the Autonomic Nervous System, 48(3), (Aug. 1994), 267-72. |
Dart, Jr., C H, et al., “Carotid sinus nerve stimulation treatment of angina refractory to other surgical procedures”, Annals of Thoracic Surgery, 11(4), (Apr. 1971), 348-59. |
De Landsheere, D, et al., “Effect of spinal cord stimulation on regional myocardial perfusion assessed by positron emission tomography”, American Journal of Cardiology, 69(14), (May 1, 1992), 1143-9. |
Dunlap, M. E., et al., “Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity”, Am J Physiol Heart Circ Physiol., 285(4), (Oct. 2003), H1632-40. |
Dunning, A. J., “Electrostimulation of the Carotid Sinus Nerve in Angina Pectoris”, University Department of Medicine, Binnengasthuis, Amsterdam; Printed by Royal VanGorcum, Assen, Netherlands, (1971), 1-92. |
Epstein, S. E., et al., “Treatment of angina pectoris by electrical stimulation of the carotid-sinus nerves”, New England Journal of Medicine, 280(18), (May 1, 1969), 971-978. |
Farrehi, C, “Stimulation of the carotid sinus nerve in treatment of angina pectoris”, American Heart Journal, 80(6), (Dec. 1970), 759-65. |
Feliciano, L, et al., “Vagal nerve stimulation releases vasoactive intestinal peptide which significantly increases coronary artery blood flow”, Cardiovascular Research, 40(1), (Oct. 1998), 45-55. |
Ferdinandy, Peter, et al., “Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning”, British Journal of Pharmacology, 138(4), (2003), 532-543. |
Flogel, Ulrich, “Myoglobin: A scanvenger of bioactive NO”, PNAS, 98(2), (Jan. 16, 2001), 735-740. |
Fromer, M, et al., “Ultrarapid subthreshold stimulation for termination of atrioventricular node reentrant tachycardia”, Journal of the American College of Cardiology, 20(4), (Oct. 1992), 879-83. |
Gewaltig, Michael T, “Vasoprotection by nitric oxide: mechanisms and therapeutic potential”, Cardiovascular Research, 55, (Feb. 14, 2002), 250-260. |
Girouard, S. D., “Method and Apparatus to Modulate Cellular Regeneration Post Myocardial Infarct”, U.S. Appl. No. 10/862,716, filed Jun. 7, 2004, 71 pgs. |
Grassi, G., et al., “Sympathetic response to ventricular extrasystolic beats in hypertension and heart failure”, Hypertension, 39(4), (Apr. 2002), 886-91. |
Grassi, Guido, et al., “Baroreflex and non-baroreflex modulation of vagal cardiac control after myocardial infarction”, Am J Cardiol., 84(5), (Sep. 1, 1999), 525-529. |
Griffith, Lawrence S.C., et al., “Electrical Stimulation of the Carotid Sinus Nerve in Normotensive and Renal Hypertensive Dogs”, Circulation, 28, (Jul.-Dec. 1963), 730. |
Heil, Jr., Ronald W., et al., “Barorelflex Stimulation System to Reduce Hypertension”, U.S. Appl. No. 10/746,134, filed Dec. 24, 2003, 78 pgs. |
Henning, R J, et al., “Effects of autonomic nerve stimulation, asynchrony, and load on dP/dtmax and on dP/dtmin”, American Journal of Physiology, 260(4 Pt 2), (Apr. 1991), H1290-H1298. |
Henning, R J, et al., “Vagal nerve stimulation increases right ventricular contraction and relaxation and heart rate”, Cardiovascular Research, 32(5), (Nov. 1996), 846-53. |
Henning, R J, et al., “Vagal stimulation attenuates sympathetic enhancement of left ventricular function”, American Journal of Physiology, 258(5 Pt 2), (May 1990), H1470-5. |
Hood Jr., W B, et al., “Asynchronous contraction due to late systolic bulging at left ventricular pacing sites”, American Journal of Physiology, 217(1), (Jul. 1969), 215-21. |
Ipastore, Joseph M., “Method and Apparatus for Modulating Cellular Metabolism During Post-Ischemia or Heart Failure”, U.S. Appl. No. 10/645,823, filed Aug. 21, 2003, 46 pgs. |
Ishise, H, et al., “Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure”, Journal of Applied Physiology, 84(4), (Apr. 1998), 1234-41. |
Jacobsson, F., et al., “The effect of transcutaneous electric nerve stimulation in patients with therapy-resistant hypertension”, J Hum Hypertens., 14(12), (Dec. 2000), 795-8. |
Janes, R. D., et al., “Anatomy of human extrinsic cardiac nerves and ganglia.”, Am J Cardiol., 57(4), (Feb. 1, 1986), 299-309. |
Jessurun, G A, et al., “Coronary blood flow dynamics during transcutaneous electrical nerve stimulation for stable angina pectoris associated with severe narrowing of one major coronary artery”, American Journal of Cardiology, 82(8), erratum appears in Am J Cardiol Feb. 15, 1999;83(4):642, (Oct. 15, 1998), 921-6. |
Kandel, Eric R, et al., “Part VII: Arousal, Emotion, and Behavioral Homeostasis”, In: Principles of Neural Science, New York : McGraw-Hill, Health Professions Division, (2000), 966-969. |
Karpawich, P. P, et al., “Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block”, Pacing Clin Electrophysiol., 22(9), (Sep. 1999), 1372-7. |
Kramer, Andrew P, et al., “U.S. Appl. No. 12/840,981, filed Jul. 21, 2010”, 77 pgs. |
Leclercq, C, et al., “Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing”, Am Heart J., 129(6), (Jun. 1995), 1133-41. |
Leutmezer, F, et al., “Electrocardiographic Changes at the onset of Epileptic Seizures”, Epilepsia, 44(3), (2003), 348-354. |
Leventhal, D K, et al., “Subfascicle stimulation selectivity with the flat interface nerve electrode”, Annals of Biomedical Engineering, 31(6), (Jun. 2003), 643-52. |
Li, M., et al., “Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats”, Circulation, 109(1), (2004), 120-124. |
Li, Qianghong, “Gene Therapy With Inducible Nitric Oxide Synthase Protects Against Myocardial Infarction via a Cyclooxygenase-2-Dependent Mechanism”, Circulation Research, 92, (2003), 741-748. |
Libbus, I., et al., “Hypertension Therapy Based on Activity and Circadian Rhythm”, U.S. Appl. No. 12/968,797, filed Dec. 15, 2010, 75 pgs. |
Libbus, I., “Implantable Systems and Devices for Providing Cardiac Defibrillation and Apnea Therapy”, U.S. Appl. No. 13/198,477, filed Aug. 4, 2011, 70 pgs. |
Libbus, I., “Integrated Lead for Applying Cardiac Resynchronization Therapy and Neural Stimulation Therapy”, U.S. Appl. No. 11/077,970, filed Mar. 11, 2005, 67 pgs. |
Libbus, I., et al., “Lead for Stimulating the Baroreceptors in the Pulmonary Artery”, U.S. Appl. No. 13/225,769, filed Sep. 6, 2011, 59 pgs. |
Libbus, I., et al., “Method and Apparatus for Synchronizing Neural Simulation to Cardiac Cycles”, U.S. Appl. No. 11/099,141, filed Apr. 5. 2005, 36 pgs. |
Libbus, I., et al., “Neural Stimulation Modulation Based on Monitored Cardiovasular Parameter”, U.S. Appl. No. 12/651,515, filed Jan. 4, 2010, 73 pgs. |
Libbus, I., et al., “System and Method for Closed-Loop Neural Stimulation”, U.S. Appl. No. 10/992,319, filed Nov. 18, 2004, 50 pgs. |
Libbus, Imad, “U.S. Appl. No. 12/783,119, filed May 19, 2010”, 94 pgs. |
Libbus, Imad, “Automatic Baroreflex Modulation Based on Cardiac Activity”, U.S. Appl. No. 10/746,846, filed Dec. 24, 2003, 75 pgs. |
Libbus, Imad, “Automatic Baroreflex Modulation Responsive to Adverse Event”, U.S. Appl. No. 10/745,925, filed Dec. 24, 2003, 73 pgs. |
Libbus, Imad, “Automatic Neural Stimulation Modulation Based on Activity”, U.S. Appl. No. 11/558,083, filed Nov. 9, 2006, 76 pgs. |
Libbus, Imad, et al., “Baropacing and Cardiac Pacing to Control Output”, U.S. Appl. No. 10/746,135, filed Dec. 24, 2003, 68 pgs. |
Libbus, Imad, “Baroreflex Modulation Based on Monitored Cardiovascular Parameter”, U.S. Appl. No. 10/939,544, filed Sep. 13, 2004, 75 pgs. |
Libbus, Imad, et al., “Baroreflex Modulation to Gradually Decrease Blood Pressure”, U.S. Appl. No. 10/746,845, filed Dec. 24, 2003, 72 pgs. |
Libbus, Imad, “Baroreflex Stimulation Synchronized to Circadian Rhythm”, U.S. Appl. No. 10/746,844, filed Dec. 24, 2003, 70 pgs. |
Libbus, Imad, “Baroreflex Stimulation to Treat Acute Myocardial Infarction”, U.S. Appl. No. 10/745,920, filed Dec. 24, 2003, 70 pgs. |
Libbus, Imad, “Baroreflex Stimulator With Integrated Pressure Sensor”, U.S. Appl. No. 10/745,921, filed Dec. 24, 2003, 72 pgs. |
Libbus, Imad, “Baroreflex Therapy for Disordered Breathing”, U.S. Appl. No. 10/864,070, filed Jun. 8, 2004, 71 pgs. |
Libbus, Imad, “Cardiac Rhythm Management Device With Neural Sensor”, U.S. Appl. No. 10/992,320, filed Nov. 18, 2004, 65 pgs. |
Libbus, Imad, “Implantable Device for Treating Epilepsy and Cardiac Rhythm Disorders”, U.S. Appl. No. 11/312,178, filed Dec. 21, 2005, 39 pgs. |
Libbus, Imad, “Lead for Stimulating the Baroreceptors in the Pulmonary Artery”, U.S. Appl. No. 10/746,861 filed Dec. 24, 2003, 21 pgs. |
Libbus, Imad, “Neural Stimulation With Avoidance of Inappropriate Stimulation”, U.S. Appl. No. 11/000,249, filed Nov. 30, 2004, 45 pgs. |
Libbus, Imad, et al., “Sensing With Compensation for Neural Stimulator”, U.S. Appl. No. 11/621,194, filed Jan 9, 2007, 69 pgs. |
Libbus, Imad, et al., “Sensing With Compensation for Neural Stimulator”, U.S. Appl. No. 10/746,847 filed Dec. 24, 2003, 71 pgs. |
Libbus, Imad, “Stimulator for Auricular Branch of Vagus Nerve”, U.S. Appl. No. 11/005,703, filed Dec. 7, 2004, 35 pgs. |
Libbus, Imad, “System to Provide Myocardial and Neural Stimulation”, U.S. Appl. No. 11/087,935, filed Mar. 23, 2005, 52 pgs. |
Lovett, Eric G, “Technique for Discriminating Between Coordinated and Uncoordinated Cardiac Rhythms”, U.S. Appl. No. 10/435,487, filed May 9, 2003, 36 pgs. |
Mannheimer, C, et al., “Epidural spinal electrical stimulation in severe angina pectoris”, British Heart Journal, 59(1), (Jan. 1988), 56-61. |
Mannheimer, C, et al., “Transcutaneous electrical nerve stimulation (TENS) in Angina pectoris”, Pain, 26(3), (Sep. 1986), 291-300. |
Mannheimer, C, et al., “Transcutaneous electrical nerve stimulation in severe Angina pectoris”, European Heart Journal, 3(4), (Aug. 1982), 297-302. |
Mazgalev, T N, et al., “Autonomic modification of the atrioventricular node during atrial fibrillation: role in the slowing of ventricular rate”, Circulation, 99(21), (Jun. 1, 1999), 2806-14. |
Millar-Craig, M W, et al., “Circadian variation of blood-pressure”, Lancet, 1(8068), (Apr. 15, 1978), 795-7. |
Min, Mart, “Electrical Impedance and Cardiac Monitoring-Technology, Potential and Applications”, International Journal of Bioelectromagnetism, 5(1), (2003), 53-56. |
Minisi, A J, et al., “Regional left ventricular deafferentation increases baroreflex sensitivity following myocardial infarction”, Cardiovasc Res., 58(1), (Apr. 1, 2003), 136-41. |
Moffitt, Julia, “Combined Neural Stimulation and Cardiac Resynchronization Therapy”, U.S. Appl. No. 11/078,460, filed Mar. 11, 2005, 35 pgs. |
Moffitt, Julia, “Transvascular Neural Stimulation Device”, U.S. Appl. No. 11/103,245, filed Apr. 11, 2005, 33 pgs. |
Murphy, D F, et al., “Intractable angina pectoris: management with dorsal column stimulation”, Medical Journal of Australia, 146(5), (Mar. 2, 1987), 260. |
Neistadt, A, et al., “Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension”, Surgery, 61(6), (Jun. 1967), 923-31. |
Nolan, J., et al., “Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure: Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart).”, Circulation, 98(15), (1998), 1510-1516. |
Ostadal, Petr, et al., “The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in patients with unstable angina and non-Q-wave myocardial infarction”, Molecular and Cellular Biochemistry, 246, (2003), 45-50. |
Paolocci, Nazareno, et al., “Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: Independence from beta-adrenergic signaling”, Proceedings of the National Academy of Sciences USA, 100(9), (Apr. 29, 2003), 5537-5542. |
Paolocci, Nazareno, “Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling”, Proceedings of the National Academy of Sciences USA, 100(9), (Apr. 29, 2003), 4978-80. |
Pastore, J. M., et al., “Multi-Site Ventricular Pacing Therapy With Parasympathetic Stimulation”, U.S. Appl. No. 12/693,660, filed Jan. 26, 2010, 20 pgs. |
Pastore, Joseph M., et al., “Multi-Site Ventricular Pacing Therapy With Parasympathetic Stimulation”, U.S. Appl. No. 10/700,368, filed Nov. 3, 2003, 18 pgs. |
Pauza, D. H., et al., “Morphology, distribution, and variability of the epicardiac neural ganglionated subplexuses in the human heart”, The Anat. Rec. 259(4), (2000), 353-382. |
Peters, T K, et al., “Temporal and spatial summation caused by aortic nerve stimulation in rabbits. Effects of stimulation frequencies and amplitudes”, Journal of the Autonomic Nervous System, 27(3), (Aug. 1989), 193-205. |
Peters, T K, et al., “The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for Angina pectoris and hypertension therapy”, Annals of Biomedical Engineering, 8(4-6), (1980), 445-58. |
Philbin, D M, et al., “Inappropriate shocks delivered by an ICD as a result of sensed potentials from a transcutaneous electronic nerve stimulation unit”, Pacing & Clinical Electrophysiology, 21(10), (Oct. 1998), 2010-1. |
Prakash, P, et al., “Asymmetrical distribution of aortic nerve fibers in the pig”, Anat Rec., 158(1), (May 1967), 51-7. |
Rosenqvist, M, et al., “The effect of ventricular activation sequence on cardiac performance during pacing”, Pacing and Electrophysiology, 19(9), (1996), 1279-1286. |
Rushmer, Robert F, “Chapter 5—Systemic Arterial Pressure”, in: Cardiovascular dynamics, Philadelphia : Saunders, (1976), 176-216. |
Salloum, Fadi, “Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase-Dependent Pathway in Mouse Heart”, Circulation Research, 92, (Apr. 4, 2003), 595-597. |
Schauerte, P, et al., “Catheter stimulation of cardiac parasympathetic nerves in humans: a novel approach to the cardiac autonomic nervous system”, Circulation, 104(20), (Nov. 13, 2001), 2430-5. |
Schauerte, P, et al., “Ventricular rate control during atrial fibrillation by cardiac parasympathetic nerve stimulation: a transvenous approach”, J Am Coll Cardiol., 34(7), (Dec. 1999), 2043-50. |
Schauerte, P. N, et al., “Transvenous parasympathetic cardiac nerve stimulation: an approach for stable sinus rate control”, Journal of Cardiovascular Electrophysiology, 10(11), (Nov. 1999), 1517-1524. |
Schauerte, P., et al., “Transvenous Parasympathetic Nerve Stimulation in the Inferior Vena Cava and Atrioventricular Conduction”, Journal of Cardiovascular Electrophysiology, 11(1), (Jan. 2000), 64-69. |
Scheiner, Avram, “Stimulation Lead for Stimulating the Baroreceptors in the Pulmonary Artery”, U.S. Appl. No. 10/746,852, filed Dec. 24, 2003, 25 pgs. |
Scherlag, B. J, et al., “Endovascular stimulation within the left pulmonary artery to induce slowing of heart rate and paroxysmal atrial fibrillation.”, Cardiovasc Research, 54(2), (May 2002), 470-475. |
Scherlag, M A., et al., “Endovascular Neural Stimulation Via a Novel Basket Electrode Catheter: Comparison of Electrode Configurations”, Journal of Interventional Cardiac Electrophysiology, 4(1), (Apr. 2000), 219-224. |
Sigurdsson, A., et al., “The Role of Neurohormonal Activation in Chronic Heart Failure and Postmyocardial Infarction”, American Heart Journal, 132(1, Part 2), (Jul. 1996), 229-234. |
Spiegel, Egbert, “A CMOS Sensor and Signal Conversion Chip for Monitoring Arterial Blood Pressure and Temperature”, IEEE International Solid-State Circuits Conference, (Feb. 20, 1992), 126-127. |
Suematsu, Yoshihiro, et al., “L-Arginine given after ischaemic preconditioning can enhance cardioprotection in isolated rat hearts”, European Journal of Cardio-thoracic Surgery, 19, (2001), 873-879. |
Takahashi, N, et al., “Vagal modulation of ventricular tachyarrhythmias induced by left ansae subclaviae stimulation in rabbits”, Japanese Heart Journal, 39(4), (Jul. 1998), 503-11. |
Thompson, Gregory W, “Bradycardia induced by intravascular versus direct stimulation of the vagus nerve”, Annals of Thoracic Surgery, 65(3), (Mar. 1998), 637-642. |
Tse, H F, et al., “Long-term effect of right ventricular pacing on myocardial perfusion and function”, J Am Coll Cardiol., 29(4), (Mar. 15, 1997), 744-9. |
Tyler, D J, et al., “Chronic response of the rat sciatic nerve to the flat interface nerve electrode”, Annals of Biomedical Engineering, 31(6), (Jun. 2003), 633-42. |
Vanoli, E., et al., “Vagal Stimulation and Prevention of Sudden Death in Conscious Dogs With a Healed Myocardial Infarction”, Circulation Research, 68(5), (May 1991), 1471-1481. |
Veerman, D P, et al., “Circadian profile of systemic hemodynamics”, Hypertension, 26(1), (Jul. 1995), 55-9. |
Verity, M A, et al., “Plurivesicular nerve endings in the pulmonary artery”, Nature, 211(48), (Jul. 30, 1966), 537-8. |
Verity, M, et al., “Pulmonary artery innervation: a morphopharmacologic correlation”, Proceedings of the Western Pharmacology Society, 8, (1965), 57-9. |
Wallick, D W, et al., “Selective AV nodal vagal stimulation improves hemodynamics during acute atrial fibrillation in dogs”, American Journal of Physiology—Heart & Circulatory Physiology, 281(4), (Oct. 2001), H1490-7. |
Waninger, M S, et al., “Electrophysiological control of ventricular rate during atrial fibrillation”, Pacing & Clinical Electrophysiology, 23(8), (Aug. 2000), 1239-44. |
Wiggers, C J, et al., “The muscular reactions of the mammalian ventricles to artificial surface stimuli”, American Journal of Physiology, (1925), 346-378. |
Woldbaek, Per Reidar, et al., “Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction”, Cardiovascular Research, 59, (2003), 122-131. |
Wolfrum, Sebastian, et al., “Acute Reduction of Myocardial Infarct Size by a Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Is Mediated by Endothelial Nitric Oxide Synthase”, J. Cardiovas Pharmacol, vol. 41, No. 3, (Mar. 2003), 474-480. |
Wunderlich, Carsten, “Acute Inhibition of Myoglobin Impairs Contractility and Energy State of iNOS-Overexpressing Hearts”, Circulation Research, 92, (2003), 1352-1358. |
Zarse, Markus, et al., “Selective Increase of Cardiac Neuronal Sympathetic Tone—A Catheter-Based Access to Modulate Left Ventricular Contractility”, Journal of the American College Cardiology, 46(7), (Oct. 4, 2005), 1354-1359. |
Zhang, Y, et al., “Optimal ventricular rate slowing during atrial fibrillation by feedback AV nodal-selective vagal stimulation”, American Journal of Physiology—Heart & Circulatory Physiology, 282(3), (Mar. 2002), H1102-10. |
Zhou, X, et al., “Prevention of high incidence of neurally mediated ventricular arrhythmias by afferent nerve stimulation in dogs”, Circulation, 101(7), (Feb. 22, 2000), 819-24. |
Ziaie, Babak, “A Single-Channel Implantable Microstimulator for Functional Neuromuscular Stimulation”, IEEE Transactions on Biomedical Engineering, 44, (Oct. 1997), 909-920. |
“U.S. Appl. No. 13/402,196, Non Final Office Action mailed Jun. 11, 2013”, 5 pgs. |
Number | Date | Country | |
---|---|---|---|
20130073000 A1 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11256907 | Oct 2005 | US |
Child | 12613094 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13402196 | Feb 2012 | US |
Child | 13678048 | US | |
Parent | 12613094 | Nov 2009 | US |
Child | 13402196 | US |